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ABSTRACT 
 
 
Cap-dependent protein translation (CdT) is dysregulated in many types of cancer and 
leads to overexpression of oncogenes promoting angiogenesis, evasion of apoptosis, and cell 
proliferation.  The protein-protein interactions (PPIs) involving eIF4E, 4E-BP1, and eIF4G1 
dynamically regulate the initiation of the CdT and are therapeutic targets of interest in treatment 
of breast, pancreatic, ovarian, and prostate cancers; successful inhibition of the CdT could also 
provide selectivity towards targeting the protein translation addicted cancers over the healthy 
cells. In order to discover potent inhibitors of the CdT initiation, full-length eIF4E protein 
interactions were targeted using a two-pronged approach: small molecule discovered via high-
throughput screening and rationally designed hydrocarbon stapled peptides.  
To conduct a high-throughput screening campaign, the assay platform catalytic enzyme-
linked click chemistry assay (cat-ELCCA) was expanded to screen against full-length PPIs to 
create PPI cat-ELCCA and implemented for the eIF4E–4E-BP1 interaction. PPI cat-ELCCA 
exhibited over 10-fold improvement in limits of detection and quantification over ELISA and 
was successfully miniaturized using automated liquid handlers with exceptional assay parameters 
(Z’ > 0.6, signal-to-background > 30). Using PPI cat-ELCCA, over 50,000 natural product 
extracts (NPE) and custom compounds were screened, of which 18 NPE fractions and 9 
compounds exhibited dose-dependent inhibition with hill slope ranging between -0.7 to -2.0. All 
the custom compounds were identified with micromolar inhibitory potency and 6 of the 9 
compounds had demonstrated direct binding interaction to target protein eIF4E. Further re-
 xvii 
isolation and iterative screening are pending for the active NPE fractions, and compound 
structure disclosures of hit molecules are awaiting approval.  
As an alternative drug discovery approach, the α-helical structure adopted by the 4E-BPs 
upon binding to eIF4E was exploited to design 4E-BP1 mimetic hydrocarbon stapled peptides 
(HCS). The lead HCS peptide HCS 4E-BP1 exhibited 5-fold greater inhibitory potency and 
eIF4E direct binding affinity (4 nM and 4 nM, respectively) than the linear 4E-BP1, 
accompanied by a 250% increase in peptide helicity. HCS 4E-BP1 successfully inhibited eIF4E 
PPIs with both 4E-BP1 and eIF4G1 in a dose-dependent manner in cellulo in presence of serum. 
Overall, the results from this two-pronged eIF4E inhibitor discovery campaign have pushed 
forward the current limits of targeting the CdT initiation and produced promising leads for 
further probe and drug development. 
 
 1 
CHAPTER 1      CAP–DEPENDENT PROTEIN TRANSLATION BIOLOGY AND 
INHIBITORS 
 
 
The cap–dependent protein translation (CdT) is upregulated by a variety of extracellular 
factors, such as mitogens, growth factors, insulin, amino acids, and overall nutrition levels 
provided to the cell3-5. CdT has garnered much investigation due to its dysregulation through the 
PI3K–AKT–mTORC1 pathway in tumor biology leading to aberrant regulation of the cell cycle, 
metabolism, genomic instability, and survival (Figure 1). Activated PI3K phosphorylates lipid 
phosphatidylinositol (3,4,5)–bisphosphate (PIP2) to phosphatidylinositol (3,4,5)–trisphosphate 
(PIP3), and PIP3 serves as the second messenger molecule that binds and recruits pleckstrin 
homology (PH) domain containing proteins such as phosphoinositide–dependent kinase–1 
(PDK1) and protein kinase B (AKT) to the plasma membrane. This co–localization leads to 
PDK1 and mTOR complex 2 (mTORC2)–dependent phosphorylation and the activation of 
AKT8-10. The activation of AKT promotes cell cycle, cell survival, and more importantly for 
CdT, cell growth through phosphorylation and deactivation of GTPase–activating protein 
tuberous sclerosis complex 2 (TSC2). This likely inhibits the intrinsic GTPase activity of Ras 
homolog enriched in brain (RHEB) to maintain its GTP–bound state. Activated mTORC1 hyper–
phosphorylates the gate–keeper of CdT, 4E binding protein 1 (4E–BP1), bound to eukaryotic 
initiation factor 4E (eIF4E) which promotes the initiation of CdT 12-14.  
 
 2 
1.1 PI3K–AKT–MTOR PATHWAY AND INHIBITORS 
 
The prevalence and the critical nature of the kinases involved in the PI3K–AKT–
mTORC1 pathway has promoted extensive investigation into the discovery of kinase inhibitors 
against these enzymes. However, while kinases are excellent “druggable” targets due to the 
well–defined substrate and target binding pockets, the cells face rapid resistance to overcome the 
 
 
Figure 1. Cap-dependent Translation. CdT is regulated through the PI3K–Akt–mTOR pathway and is 
highly dependent on the interactions of eIF4E 
 3 
inhibition of these critical signaling enzymes through various mechanisms. Despite this hurdle, 
researchers have discovered and classified five general types of kinase inhibitors targeting the 
PI3K–AKT–mTOR signaling cascade, and to an extent, the CdT initiation pathway: pan–class I 
PI3K inhibitors, isoform–selective PI3K inhibitors, pan–PI3K–mTOR kinase inhibitors, AKT 
inhibitors, mTORC1 inhibitors, and active site mTOR kinase inhibitors (Figure 2).  
Pan–class I PI3K inhibitors (GDC–0941 (Genentech), NVP–BKM120 (Novartis)) target 
the various isoforms of PI3K and their redundant functions in oncogenic signaling17 (Figure 2). 
However, this multi–targeted approach often leads to over– or under–dosing depending on the
 
 
 
Figure 2. Known small molecule inhibitors of PI3K–Akt–mTOR pathway 
 4 
disease biology and context. Furthermore, the lack of isoform selectivity generally expands 
outside of PI3K isoforms and into other PI3K–related kinase family such as mTOR18. For 
instance, GDC–0941 was reported as a potent kinase inhibitor of p110α, β, and δ isoforms with 
low nanomolar and low micromolar IC50 values in vitro and in human glioblastoma and ovarian 
cancer cell lines, respectively19. After its success through phase I clinical trial, growing concerns 
over the inherent resistance mechanisms of targeting PI3K20 led to combination therapy with 
cisplatin to treat triple–negative breast cancer. Unfortunately, the study met an early 
termination21, but GDC-0941 appears promising in a combination therapy with paclitaxel to treat 
metastatic breast cancer (NCT01740336). 
In contrast to pan–class I PI3K inhibitors, isoform–selective PI3K inhibitors target the 
disease prevalent isoform of PI3K, minimalizing the overall over– and under– dosing, and 
consequently, the toxicities associated with off–target inhibition (Figure 2). Successful 
development of p110β isoform inhibitors remain elusive due to its redundant functionalities with 
the p110α isoform, and the prevalence of solid tumors expressing malignant p110α and p110β 
had placed p110δ and p110γ inhibitor development in pre–clinical stages. p110δ inhibitor GS–
1101 is an exception, and has been approved for combination therapy with rituximab to treat 
chronic lymphocytic leukemia22. An exhaustive medicinal chemistry campaign by Novartis led 
to a p110α specific inhibitor NVP–BYL719 that exhibited greater than 50-fold selectivity over 
the p110β and p110δ isoforms in vitro, and inhibited growth of p110α–driven tumors in 
xenograft mouse models23. NVP–BYL719 is currently being investigated for its efficacy in 
neck/head tumors (NCT02145312) and advanced breast cancers (NCT02506556). The particular 
importance of p110β in certain prostate and breast cancer24 cells lacking in PTEN may drive 
future research in identifying p110β inhibitors as well.  
 5 
Investigators have also tried to capitalize on the broad inhibition profile of pan–PI3K 
inhibitors that target the structurally–related mTOR kinase by developing pan–PI3K–mTOR 
kinase inhibitors (Figure 2). Despite the increased potential for higher toxicity, the rationale 
behind this class of inhibitors lies in shutting down the crosstalk and the feedback at mTORC2 
(Figure 1). NVP–BEZ235 showed antiproliferative results early on in glioblastoma and prostate 
cancer xenograft models,25 but failed to translate as a single agent to human pathology due to 
high toxicity26. A synergized combination therapy to inhibit mTOR and p110α is being pursued 
to treat advanced nonhematologic malignancies (NCT01899053) and appears promising. 
LY3023414 (Lilly) is another hopeful molecule that caused G1 cell–cycle arrests in broad panel 
of cancer cells and in xenograft models of glioblastoma, bladder, colon, breast, ovarian and renal 
cancer27. Gedatolisib (Phase I) also showed promising results treating advanced colorectal 
cancers and ovarian cancers in combinatorial therapies28, and is currently in Phase II clinical 
trials. 
Like the other kinases in this signaling cascade, AKT also promotes growth factor–
mediated cell survival, cell proliferation and inhibits apoptosis29, and is frequently dysregulated 
in many types of cancers. Despite the critical nature of AKT, therapeutic inhibitors remain 
elusive (Figure 2). The function, tissue distribution, and ligand affinities of the three different 
AKT isoforms significantly complicates ATP-competitive inhibitor design30. However, certain 
AKT inhibitors in combination therapy with other agents appear promising and in-route to 
various stages of clinical trials. For instance, AZD5363 and Ipatasertib (GDC–0068) inhibit all 
AKT isoforms with low nanomolar potency, reduce tumor growth in certain breast cancer 
xenograft mice models31-32 and prostate cancer cells , and are currently in separate Phase II trials 
in combination with paclitaxel for the treatment of triple–negative metastatic breast cancer 
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(NCT02423603, NCT02301988). AZD5363 is also being investigated in additional Phase II 
trials for treating advanced gastric cancers (NCT02451956) and prostate cancers 
(NCT02121639); similarly, Ipatasertib is involved in a Phase II trial for treating prostate cancers 
(NCT01485861). 
Further downstream in the cascade, specific allosteric mTOR inhibitors rapamycin and 
rapalogues such as everolimus, temsirolimus and deforolimus, showed tolerated safety profiles33 
but limited therapeutic efficacy (Figure 2). Rapamycin and rapalogues bind to the intracellular 
receptor FKBP12 and the FRB domain of mTOR, thereby reducing substrate accessibility to the 
mTOR catalytic site35. These compounds selectively inhibit mTORC1 rather than the 
mTORC236-37. Rapalogues such as everolimus and temsirolimus were FDA approved to treat 
neuroendocrine tumors and advanced renal cell carcinoma38; however, others have caused 
cytostatic effects (reduction in protein translation, increased autophagy) in cells rather than 
cytotoxicity40, most likely due to the incomplete inhibition of mTORC1 and mTORC2, and the 
mTORC1–S6K1–dependent negative feedback loop. Unchecked mTORC2 results in increased 
phosphorylation of AKT at S47341, resulting in hyperactivation of AKT42 and its regulated 
downstream effectors such as FOXO proteins, cyclin D1, MDM2, caspase–9, and BAD to drive 
tumorigenesis43-45. In addition, inhibition of mTOR substrate S6K1 eliminates the negative 
feedback loop to IRS–1 upstream to PI3K activation, and limits the rapalogue efficacy. More 
importantly, rapalogues only partially inhibit mTORC1; while S6K phosphorylation is 
effectively inhibited, 4E-BP1, the master regulator of CdT, is re–phosphorylated and 
unresponsive to long-term rapalogue treatment under similar conditions. Dowling et al47-48 
showed that mTORC1–mediated inhibition of 4E–BPs led to significant reduction in cell 
proliferation, whereas inhibition of S6Ks drove reduction in cell size. This suggested that the 
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regulation of cell size and proliferation may be uncoupled in mammalian cells, and a complete 
inhibition of 4E-BP1 may be necessary to elicit cell death. Rapalogues’ incomplete inhibition of 
mTOR activity fails to kill malignant cells and have found alternative utilities as combination 
agent targeting breast cancers49-50. 
Despite the similarities between the PI3K and mTOR kinase domains and the overlapping 
inhibition profiles between the two, extensive medicinal chemistry efforts have led to kinase 
inhibitors with greater selectivity for mTOR. These active site mTOR inhibitors, or asTORis, 
bind and block the ATP–binding cleft of mTOR kinase, effectively shutting down both mTORC1 
and mTORC2 (Figure 2). PP242 and INK128 are potent asTORis that suppress both mTORC1–
dependent 4E–BP1 phosphorylation as well as tumor growth in AKT–driven rapalogue resistant 
mice models51. INK128 is currently in numerous clinical trials targeting renal cell carcinoma 
(NCT02724020), breast cancer (NCT02719691), and liver cancer (NCT02575339). AZD8055 
potently inhibits mTOR kinases with excellent selectivity profile and induces autophagy and cell 
death in cancer cells53-54, but its therapeutic efficacy remains unclear. Overall, asTORi exhibit a 
greater cytostatic effect than the rapalogues in certain cancer cell lines. However, most advanced 
tumors tend to have high eIF4E to 4E–BP ratios in response to prolonged mTOR inhibition55-59 
and may limit asTORi efficacy as a single agent. 
1.2 EIF4F BIOLOGY AND INHIBITORS 
The limited success of kinase inhibitors in treating PI3K–AKT–mTOR–driven cancers 
led to studies further downstream of mTOR, to the effectors that directly regulate the protein 
translation. In theory, successful inhibition downstream of these effectors should exert far less 
selective pressure to the cells than inhibiting the signaling kinases, and in turn, hamper the 
development of rapid resistance to the therapy. In particular, the effectors driving CdT initiation 
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are of therapeutic interest because it is the rate limiting step in protein translation and is highly 
regulated through a critical signaling hub known as 4E-binding proteins (4E-BPs) and eIF4F. 
4E–BPs are intrinsically disordered proteins (IDPs) and have little secondary structure 
while free in solution. They are critical in dynamically regulating eIF4E and the CdT in different 
tissues, but of the family (4E–BP1, 2, and 3), 4E–BP1 alterations are the most commonly 
reported in a wide range of cancers and have been extensively reviewed49, 61. Briefly, loss of 4E–
BP1 results in accelerated tumorigenesis, and non–phosphorylatable mutant actively binds and 
suppresses eIF4F complex formation, suppressing cellular proliferation and neoplastic growth62. 
Active 4E–BP1 serve as a metabolic brake and exerts significant control over fat metabolism, 
and may find utility in diabetes/obesity treatments11. Furthermore, a Drosophila model suggests 
that overexpression of Thor, a 4E–BP homolog, is able to suppress the pathologic phenotypes of 
parkinsonism, making 4E–BP mimetics as an attractive therapeutic approach to 
neurodegenerative diseases57-58.  
eIF4F is a heterotrimeric protein complex composed of the 7–methylguanosine (m7G) 
cap binding protein eIF4E, the large scaffolding protein eIF4G64, and the DNA helicase protein 
eIF4A64-65. Artificial eIF4G1 overexpression has distinct transforming activity in mouse 
embryonic fibroblasts, and in xenograft nude mice66. In inflammatory breast cancer67-69 and in 
squamous lung carcinoma, eIF4G was found to be overexpressed in the absence of 
corresponding increase in eIF4E and 4E–BP1. It is likely that eIF4G overexpression switches 
certain mRNAs from CdT to IRES–dependent translation to trigger pro-angiogenic and pro-
survival signaling cascades. 
Under starvation and nutrient deficiency, 4E–BPs bind and suppress eIF4E through a 
small canonical eIF4E binding motif (4E–BM, shared by eIF4G) – YX4LΦ where Y,X,L, and Φ 
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denote Tyr, any amino acid, Leu, and hydrophobic residue, respectively (Figure 3A), and a 
lateral binding non-canonical binding motif (4E–NBM). 4E–BMs bind on the dorsal region of 
eIF4E, the opposite side to the cap-binding site; studies have noted that binding to 4E–BP1 
suppresses the ability of eIF4E to bind effectively to m7G cap71 and provides increased 
limitations on initiating the CdT. The conserved Tyr forms a hydrogen bond to the backbone of 
the His–Pro–Leu motif of eIF4E, and R614 (eIF4G)11, 72 and R56 (4E–BP1) makes salt bridge 
with E132 on eIF4E to stabilize the interaction, as well as to partially cover the hydrophobic 
W73 (Figure 3B).   
 
Under nutrient-rich conditions, activated PI3K–AKT–mTOR leads to mTOR–dependent 
hyper-phosphorylation of 4E–BP1 and result in significant reduction in its binding affinity to 
eIF4E. eIF4G exploits this weakened interaction and competitively binds (4E–BMs of eIF4G 
also bind to the dorsal, hydrophobic surface of eIF4E73-74) to eIF4E to initiate the formation of 
the eIF4F complex, and recruits eIF4A, and eIF3 to the 40S PIC. Successful eIF4E–eIF4G 
 
 
Figure 3. eIF4E – 4E-BM structure. A) Structure of eIF4G 4E-BM (blue) and 4E-BP1 4E-BM (red) 
bound to eIF4E (yellow). B) E132 and H37-P38-Leu39 of eIF4E make critical hydrogen bond contact 
with 4E-BMs 
A B
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binding interaction increases the binding affinity to m7G cap, possibly through decreasing the 
entropy to the 4E–BP/eIF4G binding region75, and stabilizes the RNA–eIF4E complex. The 
contrasting binding affinities of 4E–BPs and eIF4G stem from the different binding affinity 
contributions that their respective C–terminal 4E–NBM make upon binding to the lateral surface 
of eIF4E . Gruner et al72 and Peter et al80 solved the structures of 4E–BMs and 4E–NBMs of 
eIF4G and 4E–BPs and concluded that the greater flexibility of the eIF4G linker connecting the 
4E–BMs to the 4E–NBMs allows for higher chances for 4E–BPs to compete with eIF4G. NMR 
spectroscopy titration experiments81-82 and small angle X–ray scattering experiments suggests 
that 4E–BP1 has a greater binding interface than eIF4G, offering additional evidence that 4E–
BP1 sequesters eIF4G effectively. And while the majority of the stimulants (growth factors, 
amino acids) modestly increase global protein translation, subsets of mRNAs containing 
relatively long, highly structured 5’ UTR that depend on eIF4F have increased translation rates. 
These subset of mRNAs are typically involved in oncogenesis such as cell proliferation (c–myc, 
CDK2, cyclin D1), evasion of apoptosis (MCL–1, BCL–2, survivin), angiogenesis (VEGF, 
FGF2), and metastasis (MMP9, heparanase)83-85. The eIF4F complex is an attractive alternative 
 
Figure 4. Inhibitors targeting the eIF4F complex 
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to shutting down and killing PI3K–AKT–mTOR driven cancers, and its inhibitors can be broadly 
categorized by targets: eIF4E, eIF4A, and eIF4G (Figure 4).  
1.2.1 EIF4E INHIBITORS 
In-depth studies have identified eIF4E as a highly dysregulated agent in oncology.  
Elevated total eIF4E in combination with 4E–BP1 hyper–phosphorylation has been observed in 
numerous types of breast and prostate cancer, and correlates strongly with a decrease in disease 
progression and overall survival. Healthy cells are reported to contain just enough free eIF4E to 
maintain basal levels of translation89-90, and increased eIF4E significantly upregulates the 
translation the mRNA sequences with excessive secondary structure in their 5’ UTR91. The 
eIF4E gene is also amplified in human breast and head and neck cancers in comparison to the 
healthy cells92. Due to its important nature, eIF4E overexpression and amplification has been 
postulated as a useful biomarker to predict therapeutic efficacy, disease progression, survival and 
relapse69, 93.  
 eIF4E binds to the 5’ terminal cap structure m7GpppN (denoted m7G), where N is the 
first transcribed nucleotide held through a 5’ to 5’ triphosphate linkage94. This site, more 
commonly referred to as the cap–binding site, is an attractive target for small molecule inhibition 
due to its defined molecular architecture. Cap analogues remain valuable tools for the eIF4E 
studies96, but the required phosphodiester moiety in the molecules results in poor permeability 
and stability in vivo97. On-going investigations are attempting to address these issues with pro–
nucleotide drugs containing phosphoramidates that are rapidly converted to the corresponding 
5’-monophopshate nucleotides in cell (4Ei–1)98-99 and with the use of virus–like particles 
(Figure 4).  
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eIF4E was targeted using antisense oligonucleotides (ASOs) with promising anti-
tumorigenic results100 (Figure 4). Further optimizations to the ASOs led to reduction in breast 
and prostate cancer xenograft mice models with minimal toxicity102, and accompanying greater 
reduction in pro-survival and pro-growth protein levels compared to the global protein level. 
ASO LY2275796 targeting the eIF4E mRNA completed its phase I trial in combination with 
irinotecan against solid tumors and irinotecan-resistant colorectal cancers103, and showed 
minimal toxicity.  
Alternatively, researchers exploited the fact that 4E-BMs adopt the α-helix secondary 
structure upon binding to eIF4E and designed α-helix mimetic stapled peptides to inhibit eIF4E 
PPIs104. The stapled eIF4G peptides yielded enhanced binding affinity and helicity compared to 
the linear peptides, but unfortunately indicated poor cell permeability105. Further medicinal 
chemistry campaign on these peptides could likely increase the cell permeability106 and 
demonstrated that eIF4F complex can be targeted through stapled peptides.  
1.2.2 EIF4A INHIBITORS 
eIF4A is an ATP-dependent RNA-stimulated DEAD-box helicase that unwinds RNA 
duplexes107 and is the reported target for Hippuristanol and Silvestrol (Figure 4). Hippuristanol 
is a steroid that prevents eIF4A from interacting with RNA108, and has shown efficacy in T–cell 
leukemia mouse models108. Silvestrol shuts down eIF4A by possibly inducing protein 
dimerization and enhancing its binding activity to RNA, effectively removing the free eIF4A 
from binding to the eIF4F complex109. Silvestrol has modest efficacies in breast cancer and 
prostate cancer xenograft mouse models108. eIF4A inhibitors have not yet progressed to the 
clinical trials due to their rapid clearance110-112. However, eIF4A inhibitors (as single agents) 
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remain well-tolerated and may help restore chemosensitivity to selected types of cancers and 
synergize with other chemotherapeutic agents. 
1.2.3 EIF4G INHIBITORS 
 
The growing evidence of the eIF4E nexus in cancer, metabolic, and neurodegenerative 
pathology led to a few high–throughput screening (HTS) campaigns to identify novel small 
molecule inhibitors of eIF4E – eIF4G PPIs. 4EGI–1, 4E1RCat, and 4E2RCat are documented 
inhibitors of this PPI (Table 1) , discovered through HTS targeting the PPI between the 4E–BMs 
of eIF4G/4E–BP1 and eIF4E. 4EGI–1 effectively inhibited CdT, proved to be active in 
numerous cancer cell lines, and reduced tumor growth in xenograft breast cancer and melanoma 
 
Table 1. Chemical structures and the inhibitory activities of inhibitors targeting the eIF4G – eIF4E 
interaction 
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mice models115. 4E1RCat and 4E2RCat target the 4E–BMs and inhibit both 4E–BP1 and eIF4G 
from binding to eIF4E116. The initial studies indicated that 4E1RCat restores the 
chemosensitivity in myc–driven lymphoma model, and could find utility in treating coronavirus 
infection as well117. Despite the in vitro evidence of 4EGI–1 and 4E1RCat potency, there are no 
on-going clinical trials utilizing these small molecules yet, likely due to the possible target 
promiscuities and their structural similarities to PAIN compounds.  
More recently, Feng et al discovered another eIF4F disrupting molecule, SBI-756118. 
Although SBI-756 was an analog derived from the AKT kinase inhibitor BI‐69A111, the 
investigators identified eIF4G1 as a binding protein and that in combination with BRAF 
inhibitors, SBI-756 had reduced the formations of BRAF inhibitor resistant tumors. The 
investigators are currently working on the next generation of this molecule for clinical trials.  
1.3 CONCLUSION 
The current literature on hyperactivated PI3K-AKT-mTOR pathology and medicine 
makes two things very clear, i) that targeting The CdT in pathological cells through kinase 
inhibitors up-stream to the effectors is imperfect, and ii) prior drug discovery efforts to target the 
downstream eIF4F complex have yet to reveal compounds amenable for drug development. The 
Garner group has been working on the latter issue with a simple thought in mind: imperfect tools 
lead to imperfect products. These imperfect compounds are the natural products of imperfect 
tools, or more specifically, the HTS assays used to identify the hit compounds during the 
discovery stage. For instance, although fast and inexpensive, the fluorescence-based HTS 
methods such as fluorescence polarization suffer from well-documented poor sensitivity, high 
false positive and negative hits of aggregators and fluorescence quenchers. A more robust, 
sensitive, and applicable HTS methods would greatly improve the chances of identifying a 
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scaffold capable of inhibiting strong PPIs for further medicinal chemistry while minimizing the 
time and resources. 
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CHAPTER 2      DESIGN AND DEVELOPMENT OF PPI CAT–ELCCA1 
 
 
In the present toolbox of high–throughput screening (HTS) assays for PPIs, a missing 
piece is the ability to screen against full–length protein systems in a non-cellular format. The 
most commonly used biochemical assays for PPIs are fluorescence polarization (FP), 
fluorescence resonance energy transfer (FRET), and time–resolved FRET (TR–FRET)1. 
Although easy to implement due to their homogeneous conditions, these assays are mostly 
limited to the analysis of motif–domain or domain–domain interactions due to size and labeling 
requirements1-2. Thus, by using these methods, probe discovery efforts are focused solely on hot 
spot interactions, while eliminating the possibility of targeting potentially more druggable 
allosteric binding sites. Moreover, these approaches require structural knowledge about the PPI 
in order to design appropriate peptide substrates (e.g. FP) or for proximity–matched labeling 
(e.g. FRET), which also may be difficult, particularly for large or disordered proteins, as the 
cases of 4EGI–1 and 4E1RCat HTS campaigns have shown. Other disadvantages of these 
approaches include single-turnover readout, which limits the sensitivity of the measurement and 
compound interference by assay-specific interferents (e.g. fluorescent molecules or fluorescence 
quenchers) yielding many false positive and negative hits. In order to efficiently assay and 
discover chemical modulators of full–length PPIs, which are more biologically relevant, ELISA 
and SPR are better suited despite their disadvantages with respect to lower screening throughput. 
Specifically, the Garner group has been interested in developing novel assays that retain the 
                                                 
1 This work was published in ACS Combinatorial Science in 2017 under the title “High-Throughput Chemical 
Probing of Full-Length Protein–Protein Interactions”. Co-authors include: Menon, Arya (eIF4G1 protein 
preparation); Mitchell, Dylan (eIF4G1 plasmid preparation); Johnson, Oleta (eIF4E protein preparation) 
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advantages of ELISA and minimize its disadvantages while expanding its applications. Garner et 
al. invented a new platform assay technology termed catalytic enzyme-linked click chemistry 
assay, or cat–ELCCA, as a robust method to monitor the fatty acid acyltransferase activity of 
Ghrelin O‐Acyltransferase1, 3-4. Later on, cat–ELCCA was re-conceptualized to target DICER–
driven maturation of pre–miRNAs and eIF4E PPIs (Figure 5A). The latter assay platform was 
termed PPI cat–ELCCA6-7. 
 
PPI cat-ELCCA derives its origin from ELISA (Figure 5B), and as such, share its core 
advantages (high sensitivity and low chemical interference) to its disadvantages (mid-throughput 
 
Figure 5. cat–ELCCA and ELISA. A) generic schematic of cat-ELCCA. B) comparison of ELISA and 
PPI cat-ELCCA 
A
B
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and heterogeneous assay conditions). Briefly, one of the binding partners in the PPI is 
immobilized to the well surface through passive adsorption to the plastic (ELISA) or through 
tag–affinity driven interactions (PPI cat-ELCCA, biotin–streptavidin). Following the 
immobilization and the subsequent washing, the second binding partner is then added. In ELISA, 
after another brief wash, the binding event is then detected through the antibody specific to the 
second binding partner and quantified through an enzyme–conjugated secondary antibody. PPI 
cat-ELCCA eliminates the need for antibodies and relies on the click-chemistry reaction between 
the protein complex and chemically modified HRP for direct detection.  
Although few in number, (9 primary screens as of January 2018) ELISA has been used 
for primary screening campaigns. In general, ELISA is suboptimal for the large primary 
screening due to its three greatest drawbacks: it is labor intensive, it has relatively low 
throughput in comparison to FP and TR–FRET and plagued by the inconsistencies and 
availabilities of antibodies. The washing steps must be automated and optimized through robotic 
handlers, and in most cases, the plates must be manually handled in between the washing steps. 
HTS campaign using ELISA could potentially be days or even weeks longer than a similar 
campaign using FP and TR–FRET. Furthermore, the lot–to–lot and even vial–to–vial variations 
in sensitivity and selectivity of commercially available antibodies plague researchers and 
contributes to the rising undependability of published studies.  
Despite the glaring disadvantages of HTS ELISA, its strengths could enable screening of 
difficult PPI targets. ELISA utilizes readily available instrumentation and reagents in a typical 
laboratory, from generic fluorescence/absorbance/luminescence plate readers to primary and 
secondary antibodies of interest. Its enhanced sensitivity from enzyme–driven signal detection 
enables compound screening to be performed at low nanomolar concentrations, saving reagents, 
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and more importantly, dramatically increasing the chances of discovering even weak inhibitors 
to a particularly strong PPI. This advantage is critical in screening for inhibitors of eIF4E PPIs 
because of the reported high binding affinity of 4E–BP1 and eIF4G to eIF4E. Although labor 
intensive, the washing steps separate the screening step and the signal detection step, reducing 
the library chemical interference (fluorescence/luminescence quenchers, fluorophores, etc.) 
while greatly increasing the diversity of potential libraries. Furthermore, optimized protein 
immobilization (specifically enzymes) in biotechnology often leads to greater temperature, pH, 
and organic solvent stabilities1-2; thus, protein engineering that accounts for proper active 
orientation, and distance from the immobilized surface could allow screening of the PPIs 
involving unstable protein(s). PPI cat-ELCCA had eliminated the washing and the incubation 
steps required for the secondary antibodies, which led to reduction in assay time and 
improvements in HTS statistics.  And while the first generation of cat-ELCCAs utilized 
CuAAC3-4, 8 in the assay design, the second generation cat-ELCCAs use IEDDA which provided 
far superior reaction kinetics, greater throughput and HTS screening statistics, and required less 
labor. In design and practice, PPI cat-ELCCA is a faster and more sensitive alternative to ELISA 
for PPI drug discovery campaigns. 
2.1 EFFORTS TO DEVELOP PepPI CAT–ELCCA 
2.1.1 RESEARCH DESIGN 
Prior to the invention of PPI cat–ELCCA, the Garner group sought to develop an 
alternative assay for the biological systems in which full–length proteins were unavailable and 
FP/TR–FRET HTS campaigns had been unsuccessful. To fill this unique target gap – especially 
in regard to the CdT initiation and the eIF4E interactions – the Peptide–Protein Interaction cat–
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ELCCA, or PepPI cat–ELCCA was developed (Figure 6). For all the proposed advantages of 
developing HTS campaign assays against full–length PPIs, sometimes the full interaction is 
impossible to recapitulate in vitro. For example, the full–length eIF4E–eIF4G1 interaction was 
unsuitable to be developed into a HTS campaign due to difficult preparation and procurement of 
eIF4G1 for the assays and its instability. A comprehensive study in 2003 revealed that only about 
10% of full–length proteins from Eukarya can be expressed and purified in E. coli systems6-7, 
and that the probability of success decreases significantly for proteins with molecular weights 
greater than 60 kDa. Unsurprisingly, the shorter and simpler domains could be expressed as a 
recombinant protein or synthesized as peptides, and are less prone to poor translation, 
misfolding, and aggregation than the full–length protein. Thus, for many targets of interest, 
peptide–protein interactions and FP/TR–FRET assays may be one of the few options for 
conducting HTS campaigns.  
In PepPI cat–ELCCA, the biotinylated protein is immobilized in the wells of a 
streptavidin–coated microtiter plate. Following the protein immobilization, a click chemistry-
armed peptide-binding partner is added to form the peptide–protein interaction. In this assay 
 
Figure 6. PepPI cat–ELCCA CuAAC schematic 
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platform, the direct binding affinities of the chemically modified peptide probes could be 
measured without the need for immuno-affinity tags, antibodies, and SPR instrumentation. It 
would also benefit from the increased protein complex stability (temperature, pH, organic 
solvent, and etc.) from protein immobilization11 and exhibit reduced screening chemical 
interference while maintaining the high sensitivity and the robustness of ELISA.  
2.1.2 PROTEIN LABELING 
 
cat–ELCCAs utilizes chemically labeled proteins: one with a biotin moiety for 
immobilization to the streptavidin-functionalized plate, and another with a click chemistry 
handle (alkyne, azide, TCO, or mTET) for a bioconjugation to the HRP. A common strategy to 
label proteins is by using amine reactive crosslinkers such as N–hydroxysuccinimide (NHS) 
esters to target the surface-exposed lysines (Figure 7A) on the proteins. However, this  approach 
 
Figure 7. The mechanism of Halotag Protein labeling. A) Amine–reactive crosslinker NHS ester forms 
amide with surfaced exposed lysines on the protein, B) chloro–alkane linkers covalently react with 
Asp106 in the Halotag active site 
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can randomly functionalize the target protein with varying numbers of desired chemical groups 
and will result in heterogenous biophysical orientations during the immobilization and the 
interaction. As previously discussed, the protein immobilization step could potentially be 
advantageous with the right protein engineering to increase protein stability and activity; thus, 
the bioconjugation method should yield one functional group per protein, and on the identical 
residue(s). Both PepPI and PPI cat–ELCCAs were designed using HaloTag–fusion™ proteins 
(HT). HT is a 34 kDa enzymatic tag that covalently reacts to a chloroalkane ligand, displacing 
the electrophilic chlorine in a SN2 reaction (Figure 7B). HT fusion protein limits labeling to just 
one chemical group per protein on HT Asp106, and provide a homogenous labeling.  
2.1.3 PEPPI CAT–ELCCA CLICK CHEMISTRY 
 Alkynyl 4E–BP1 peptide was prepared through solid phase peptide chemistry and 
verified by reacting with azido-functionalized rhodamine; azido-HRP was labeled with a  
diazotransfer reagent1 and verified similarly with alkynyl-functionalized rhodamine. The 
reactions were tested using both THPTA (Tris(3–hydroxypropyltriazolylmethyl)amine) and 
TBTA (Tris[(1–benzyl–1H–1,2,3–triazol–4–yl)methyl]amine) as the CuAAC ligand (Figure 
8A). However, while both post–translational modification cat–ELCCA3-4 and pre–microRNA 
maturation cat–ELCCA had worked effectively using the ligand THPTA, PepPI cat–ELCCA 
failed under the identical conditions and only yielded notable signal–to–background (S/B) using 
TBTA (Figure 8B). The lack of translation between the reactivities of immobilized and in-
solution substrates highlights the difficulties of bioconjugation and the necessary assay 
developments for each biological systems and substrates. 
 Unfortunately, the IEDDA reaction utilized by the second-generation cat-ELCCAs1, 3 
was not amenable to PepPI cat–ELCCA and the assay could not capitalize on its superior  
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reaction kinetics. Despite the noted stability of methyl–tetrazine (mTET) to trifluoroacetic acid 
(TFA) as shown by the synthesis of mTET HaloTag probe (Scheme 1), global TFA deprotection 
of the mTET functionalized 4E–BP1 peptide had failed to materialize the desired product. 
Although the mTET moiety had previously been successfully incorporated into either of the 
termini and into the mid– peptide sequence15, these peptides all consisted of amino acids without 
any side–chain protecting groups (V, F, A, and G). Since the global TFA deprotection of 4E–
BP1 peptide releases highly reactive protecting groups, the added scavengers may be insufficient 
to prevent the side reactions with mTET moiety. The incorporation of the trans–cyclooctene 
(TCO) moiety into the 4E–BP1 peptide was not attempted due to its documented isomerization 
under global deprotection conditions16.  
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Figure 8. PepPI cat-ELCCA proof-of-concept. A) in solution CuAAC conditions to conjugate alkynyl 
4E–BP1 peptide and azido Rhodamine, B) CuAAC ligand THPTA fails to elicit notable S/B ratio 
whereas TBTA shows S/B of 4.2. ++, alkynyl 4E–BP1 and biotin eIF4E, +– alkynyl 4E–BP1 only (n = 3, 
shown as the mean ± SD) 
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2.1.3 PEPPI CAT–ELCCA ASSAY DEVELOPMENT 
Supplementing the assay and the wash buffers with BSA significantly improved the S/B 
between the positive interaction (++) and the competition (++ competition) from 1.4 to 10.1 
(Figure 9A). BSA is a common blocking reagent utilized in ELISAs, western blotting, FP, and 
other laboratory techniques. In PepPI cat–ELCCA, BSA likely prevented nonspecific adherence 
of the 4E–BP1 peptides (both alkynyl and native) and azido-HRP to the well surfaces. In fact, the 
high signal observed in absence of both BSA and alkynyl 4E–BP1 peptide indicated that the 
CuAAC condition alone was sufficient to cause nonspecific adherence of azido–HRP, which 
could be prevented by using a commercial blocking reagent (Figure 9B). Alkynyl 4E-BP1–
eIF4E interaction failed to reach saturation signal above 5 µM despite the reported binding 
affinity of 15 nM to 85 nM by SPR16 (++, Figure 9C), which indicated possible peptide 
aggregation at the high concentrations. However, the assay did demonstrate a complete inhibition 
of alkynyl 4E-BP1 peptide–eIF4E interaction-dependent signal in the presence of the unlabeled 
4E-BP1 protein, and only a slight loss in presence of BSA (Figure 9C); confirming that the 
observed signal in the PepPI cat–ELCCA was indeed 4E-BP1–eIF4E interaction specific.  
 
Scheme 1. Synthetic schemes of Biotin- (R1), mTet- (R2), and alkynyl- (R3) Halotag ligands. 
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2.1.4 PEPPI CAT–ELCCA CONCLUSION 
Although PepPI cat-ELCCA was confirmed to be 4E-BP1–eIF4E interaction dependent, 
and the nonspecific signals arising from CuAAC conditions had been resolved, the extensive 
assay optimizations to arrive to a modest S/B with data fluctuations made it undesirable for HTS 
screening. Successful transition of PepPI cat-ELCCA to IEDDA chemistry may have improved 
its screening statistics; however, with the successful development of PPI cat-ELCCA, PepPI cat-
ELCCA had lost much of its relevance for the HTS purposes. The suspected peptide aggregation 
was later confirmed through PPI cat-ELCCA (Figure 16D) but was never resolved despite the 
extensive peptide sequence optimizations, buffer salts and ionic strength variations, and 
additions of reducing and/or chaotropic reagents. In summary, PepPI cat-ELCCA demonstrated 
 
 
Figure 9. PepPI cat-ELCCA development. A) BSA incubation in PepPI cat–ELCCA dramatically 
increases the S/B between a positive interaction (++) and competition (++ competition), B) Synthetic 
Block BufferTM reduces the nonspecific binding of HRP induced by CuAAC condition, C) the unlabeled 
HT 4E–BP1 eliminates PepPI cat–ELCCA signal (++ WT) whereas equivalent addition of BSA does not 
(++ BSA). All experiments were conducted in triplicates (n=3) and shown as the mean ± SD 
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the difficulties of designing peptide-protein interaction-based assays. Their limited solubilities 
and susceptibilities to the aggregation requires careful peptide sequence design, and a difficult 
compromise between optimizing for the desired binding affinity and for the necessary 
reagent/assay conditions of the HTS campaign. Although the development of HTS capable PepPI 
cat-ELCCA proved unsuccessful, it laid the foundation for the design and the establishment of a 
more biologically relevant, full-length protein interaction targeting PPI cat-ELCCA. 
2.2 PPI CAT-ELCCA 
As previously noted, PPI cat-ELCCA shares much of its foundation with ELISA and 
PepPI cat-ELCCA. Similar to PepPI cat-ELCCA, a biotinylated protein is first immobilized in 
the wells of a streptavidin-coated microtiter plate. However, in place of adding in a click 
chemistry-armed peptide-binding partner, the wells are incubated with a click chemistry-armed 
protein-binding partner to form the PPI. Detection occurs through a click reaction with a labeled 
horseradish peroxidase (HRP), followed by addition of a HRP substrate and chemiluminescence 
measurement. Importantly, this catalytic system retains the major advantages of ELISA and 
minimizes the disadvantages of ELISA by eliminating the requirement for antibodies, which 
results in two distinct benefits: 1) the facile implementation to PPI targets for which monoclonal 
antibodies may not already exist or are difficulty to generate against, and 2) the removal of one 
washing step without sacrificing the sensitivity and the low compound interference. As a proof-
of-concept, PPI cat-ELCCA was developed for two interactions that play a crucial role in the 
initiation of the CdT, between that of eIF4E−4E-BP1 and of eIF4E−eIF4G. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 PROTEIN LABELING 
Alkyne-, mTet-, and biotin-functionalized chloroalkane HT probes were synthesized 
(Scheme 1) and purified. Azide–NHS esters and TCO–NHS esters were used to label HRP; the 
biophysical orientations and the varying number of labeling (3–4 surface-exposed lysines that 
were labeled) on HRP were of minimal concern, as the reactive functional groups were already 
restricted by the active protein complexes. The successful labeling and activity of the chemical 
groups were verified (Figure 10A) and the biotin labeling was verified through streptavidin–
HRP blot (Figure 10B).  
 
2.3.2 PROOF OF CONCEPT: CUAAC PPI CAT–ELCCA 
PPI cat–ELCCA was first established with eIF4E–4E–BP1 as a model interaction and 
using CuAAC as the click chemistry reaction (Figure 11A). Biotinylated eIF4E was first 
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Figure 10. 4E-BP1, eIF4E and eIF4G Labeling. A) PPI cat–ELCCA protein labeling verification. B) 
verification of successful biotinylation 
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immobilized in the wells of a 384-well streptavidin plate and incubated with alkynyl-4E–BP1. 
Following a click reaction with azido-HRP, the wells were treated with SuperSignal West Pico 
and chemiluminescence signal was measured. In this proof-of-concept, alkynyl-4E–BP1 showed 
high luminescence and the addition of unlabeled WT HaloTag-4E–BP1 (WT 4E–BP1) reduced 
the signal to the base level (Figure 11B). The interaction was also found to be dose-dependent, 
yielding apparent Kd values of 54 ± 5 nM for 4E–BP1–eIF4E interaction (++, Figure 11C), 
which were comparable to the hot spots that drive the interaction. Furthermore, the addition of 
WT 4E–BP1 reduced the luminescence signal, indicating that the observed interaction was 
specific to that between eIF4E–4E–BP1. 
 
Figure 11. CuAAC PPI cat-ELCCA. A) CuAAC PPI cat–ELCCA schematics. B) Proof of concept for 
CuAAC PPI cat–ELCCA. Addition of the WT 4E–BP1 lowers luminescence by 25-fold C) The 
interaction is dose dependent, and addition of WT 4E–BP1 reduces the number of the active complexes. 
All experiments were conducted in triplicates (n=3) and shown as the mean ± SD. 
 
 39 
2.3.3 PROOF OF CONCEPT: IEDDA PPI CAT–ELCCA 
Although CuAAC yielded acceptable results, the reaction conditions were labor 
intensive. Thus, PPI cat–ELCCA was re-modeled to the second–generation approach utilizing 
inverse–electron demand Diels–Alder (IEDDA) chemistry (Figure 12A), in which the HRP and 
4E-BP1 were labeled with TCO and mTET, respectively. Previously, the Garner group had 
demonstrated that due to its kinetic superiority, replacing the first-generation CuAAC click 
chemistry detection step16 with IEDDA yielded improved sensitivity and reproducibility, 
enabling automated HTS. Similar to CuAAC PPI cat–ELCCA, biotinylated eIF4E or eIF4G was 
first immobilized in the wells of a 384–well streptavidin plate and incubated with mTet-4E–BP1 
or -eIF4E, respectively. Of note, for the eIF4E−eIF4G PPI, eIF4G was immobilized due to its 
large size (220 kDa) and crude preparation from overexpressing HEK293T cells (Figure 12B), 
as eIF4G cannot be purified to homogeneity. Following the click reaction with HRP-TCO, the 
wells were treated with SuperSignal West Pico and chemiluminescence signal was measured. 
The preliminary experiments using IEDDA were successful and >500-fold chemiluminescence 
signal increases were observed for both PPIs, whereas controls without either protein yielded no 
signal as expected (Figure 12B). Importantly, this is the first time that the full-length eIF4G 
protein has been used in a biochemical assay of eIF4E binding, as the previous reports have 
focused solely on eIF4G peptide or protein fragments due to its size, instability, and limitations 
of the assay formats used (FP and TR–FRET).. The interactions were also found to be dose–
dependent, yielding apparent Kd values of 3.8  0.7 and 8.3  0.5 nM for 4E–BP1 and eIF4G 
binding, respectively (Figure 12C). These values are in line with previous biophysical affinity 
measurements of 4E–BP1 protein and eIF4G fragments for eIF4E since the full–length PPIs 
should yield greater affinity to eIF4E. Thus, IEDDA PPI cat–ELCCA had significantly 
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improved the overall sensitivity of the assay and revealed the extent to which CuAAC PPI cat–
ELCCA had understated the interaction affinity. As previously mentioned, the screening 
conditions must account for the native binding affinity of the interaction and ensure that assay is 
performed ideally under the saturating conditions to improve the chances of getting hits in HTS 
campaigns. Fortunately, IEDDA PPI cat–ELCCA has the sensitivity to allow screening to be 
done at mere single digit nanomolar concentrations of the protein complex. 
2.3.4 EIF4E IMMOBILIZATION STABILITY 
Of note, a complete loss of signal (eIF4E−eIF4G) or drastic increase in the apparent Kd 
(eIF4E−4E–BP1) was observed when eIF4E was exposed to a freeze/thaw cycle for long–term 
storage (Figure 13). Interestingly, this phenonmenon was observed only when eIF4E was free in 
solution as the mTet-labeled substrate. Because the eIF4E instability is well-documented in the 
 
Figure 12 IEDDA PPI cat-ELCCA. A) PPI cat–ELCCA for eIF4E PPIs. mTet = methyltetrazine; TCO = 
trans–cyclooctene. For the eIF4E−4E–BP1 assay, eIF4E was immobilized and 4E–BP1 mTet labeled. For 
the eIF4E−eIF4G assay, eIF4G was immobilized and eIF4E mTet labeled. B) Proof–of–concept data. X 
refers to protein. C) Kd,app measurement. All experiments were conducted in triplicates (n=3) and shown 
as the mean ± SD. 
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literature, the immobilization likely enhances its stability during the assay. A similar result 
was observed with eIF4G, and the assay using mTet-eIF4G in solution failed. As previously 
noted, increased protein stability through immobilization is not a novel phenomenon; thus, 
despite the associated washing steps, immobilization–based assay platforms like ELISA, SPR, 
and now PPI cat–ELCCA may enable a more comprehensive analysis of the full-length proteins 
that exhibit stability issues.  
2.3.5 PPI CAT–ELCCA AND ELISA COMPARISON 
To provide a direct comparison of PPI cat–ELCCA to ELISA, binding affinities of the 
eIF4E−4E–BP1 PPI was measured through ELISA, which yielded a Kd of 19  1 nM (Figure 
14A). Next, limit of detection (LOD) and limit of quantitation (LOQ) parameters were 
determined for both assays. PPI cat–ELCCA exhibited a superior limit of detection (0.014 ng for 
PPI cat–ELCCA and 0.15 ng for ELISA) and a limit of quantitation (0.43 and 0.047 ng, 
 
Figure 13. eIF4E in PPI cat-ELCCA. The alternative immobilization strategy, in which 4E–BP1 was 
immobilized and mTET–eIF4E was incubated, drastically reduced the S/B ratio and the apparent affinity. 
All experiments were conducted in triplicates (n=3) and shown as the mean ± SD. 
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respectively) than ELISA by approximately 10–fold. The LOD and LOQ differences reasonably 
explains the observed 
differences in the measured binding affinities, and offers a concrete evidence that PPI cat–
ELCCA has greater sensitivity than ELISA. In addition, PPI cat–ELCCA was faster by 2 h due 
to the elimination of additional incubation step with the enzyme–linked secondary antibody and 
the related washing steps. A similar ELISA for the eIF4E−eIF4G PPI could not be performed, 
due to the necessity of using crude eIF4G protein, which was contaminated with endogenous 
 
Figure 14. Sensitivity comparison between PPI cat–ELCCA and ELISA. A) ELISA yielded Kd of  19  1 
nM , in comparison to that of PPI cat–ELCCA at 3.8 ± 0.7. B) Linear calibration curve generated from 
each assay. LOD and LOQ were calculated (LOD = 3.3/m; LOQ = 10/m; where  and m is the 
standard deviation and the slope of the response in the linear range. For ELISA, LOD = 0.15 ng and LOQ 
= 0.47 ng. For PPI cat–ELCCA, LOD = 0.014 ng and LOQ = 0.043 ng. All experiments were conducted 
in triplicates (n=3) and shown as the mean ± SD. 
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eIF4E and would yield false results as the primary antibody would detect both endogenous and 
exogenous eIF4E.  
2.3.6 IEDDA PPI CAT–ELCCA VALIDATIONS 
Because the goal was to use PPI cat–ELCCA to discover inhibitory chemical probes, the 
competitive effect of 4E–BP1 proteins and of the previously reported small molecule modulators 
of the eIF4E−eIF4G PPI were assayed24. WT 4E–BP1 protein was able to readily compete with 
mTET–4E–BP1 (Figure 15A, IC50 value of 11.0  0.1 nM); whereas, null–binding 4E–BP1 
mutants exhibited reduced inhibition of the PPI–dependent signal (IC50 values
 
of 67, 370, 618 and 41,000 nM for M60A, L59A, Y54A, and L59A/M60A mutants, 
respectively). For the small molecules, 4EGI–1 and 4E1RCat, apparent IC50 values of 12  1 
 
Figure 15. Characterization of PPI cat–ELCCA for chemical probe discovery. (A) Inhibition by 4E–BP1 
proteins. (B), (C) Inhibition of eIF4E−eIF4G and eIF4E−4E–BP1, respectively, by 4EGI–1 and 4E1RCat. 
(D) Inhibition by 4E–BP1 peptide. All experiments were conducted in triplicates (n=3) and shown as the 
mean ± SD. 
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and 3.1  0.4 M for eIF4E−eIF4G and 5.1  0.1 and 1.8  0.6 M for eIF4E−4E–BP1 were 
measured, respectively (Figures 15B, 15C). Importantly, this is the first study demonstrating that 
these molecules can directly disrupt eIF4E−4E–BP1 binding.24 For 4EGI–1, this is in contrast to 
its initial report, which indicated that it stabilized 4E–BP1 binding to eIF4E in cells. However, 
this is likely due to its complex cellular activity, and inhibition of 4E–BP1 binding by this 
molecule has never been analyzed in a biochemical or biophysical assay. 4EGI–1 was recently 
found to bind allosterically to eIF4E at its lateral surface, which is distinct from that of eIF4G 
and 4E–BP1, which competitively bind at the dorsal surface. Since both eIF4G24 and 4E–BP1 
contain second, yet weaker, binding sites at this lateral surface of eIF4E, it is not surprising that 
4EGI–1 would disrupt the binding of both. It is important to note, however, that both 4EGI–1 
and 4E1RCat exhibit potentially non–specific inhibitory mechanisms for the PPIs, as indicated 
by their steep Hill slopes (< –2). On the other hand, a 4E–BP1 peptide (Gly49–Asn64) exhibited 
specific inhibition of both PPIs with apparent IC50 values of 27  4 nM and 74  5 nM for the 
eIF4E−eIF4G and eIF4E−4E–BP1 PPIs, respectively (Figure 15D), and Hill slopes of –1. At the 
higher dosage of linear 4E–BP1 peptides, a steep increase in the luminescence was observed (10 
– 100-fold greater intensity than the negative controls) which was likely contributed by the linear 
4E–BP1 peptides’ poor solubility, a high tendency to precipitate from solution (from minor, 
erratic perturbations like sudden change in temperature, pH, solvent composition, and mixing), 
and aggregation. Subsequent testing of known aggregators in PPI cat–ELCCA exhibited similar 
trends, and suggested the problem was in peptide aggregations. 
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2.4 CONCLUSION 
PPI cat–ELCCA is a new assay technology that readily facilitates the analysis of the full–
length PPIs. Despite its similarity to ELISA, it boasts about 10–fold greater LOD and LOQ due 
to the elimination of the primary and the secondary antibodies, and the respective washing steps. 
PPI cat–ELCCA was readily adapted to two PPIs of interest, eIF4E–4E–BP1 and eIF4E–eIF4G1; 
as PPIs are of great interest in both basic science and drug discovery, this assay system will 
provide a key methodology in advancing various PPI–targeted investigations and chemical probe 
discovery. The robustness and notable resistance to assay interfering chemicals make PPI cat–
ELCCA an ideal assay system to screen complex, yet chemically diverse libraries such as the 
natural product extract (NPE) library. Furthermore, the high sensitivity of the assay allows HTS 
screening to be completed at protein complex concentration as low as 4 nM, increasing the 
likelihood of finding a disruptor of this high affinity interaction and reducing the chances of 
protein aggregation and precipitation. In summary, PPI cat–ELCCA is highly robust and 
sensitive, and readily accommodates potentially unstable proteins and complexes for HTS 
campaigns. 
2.5 EXPERIMENTAL 
2.5.1  GENERAL INFORMATION 
2.5.1.1  GENERAL CHEMISTRY METHODS 
Reactions were carried out under a nitrogen atmosphere with dry, freshly distilled 
solvents under anhydrous conditions, unless otherwise noted. Reaction were monitored by thin–
layer chromatography (TLC) carried out on 0.25–mm SiliCycle silica gel plates (60F–254) using 
UV–light (254 nm) or ninhydrin staining.  
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RP–HPLC was performed using binary gradients of solvents A and B, where A is 0.1% 
HCO2H in water and B is 0.1% HCO2H in acetonitrile (analytical RP–HPLC) or 0.1% HCO2H in 
methanol (preparative RP–HPLC). Analytical RP–HPLC was performed using an Agilent 1260 
Infinity HPLC equipped with a ZORBAX Eclipse SB–C18 column (4.6 × 150 mm; 5 μm) at a 
flow rate of 1 mL/min, with detection at 214 and 254 nm. Preparative RP–HPLC was performed 
using an Agilent 1260 Infinity HPLC equipped with a PrepHT SB–C18 column (21.2 × 150 mm; 
5 μm) at a flow rate of 18mL/min, with detection at 214 and 254 nm. In all cases, fractions were 
analyzed off–line using an Agilent Q–TOF HPLC–MS. 
NMR spectra were recorded on Varian 500MHz instrument. The following abbreviations 
are used to indicate the multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, 
broad.  
 Fmoc–protected amino acids and Rink amide MBHA resin were purchased from P3 
Biosystems and used as received. TCO–PEG4–NHS was purchased from Click Chemistry Tools 
and used as received. 
2.5.1.2  GENERAL ASSAY AND BIOLOGY METHODS 
Chemiluminescence data was collected on a BioTek Cytation3. Gels were imaged on a 
ProteinSimple Fluorchem M Gel Imager. BL21DE3 E. coli were used for protein expression. 
HEK293T cells were cultured in DMEM (Corning) supplemented with 2 mM L–glutamine, 1% 
Penicillin/streptomycin (Gibco) and 10% FBS (Atlanta Biologicals). Cells were incubated at 37 
C in a humidified atmosphere containing 5% CO2. Horseradish peroxidase (HRP), streptavidin–
coated 384–well plates (white, high binding capacity; cat #15505), and SuperSignal West Pico 
Chemiluminescent substrate kit were purchased from Pierce. eIF4GI–HaloTag human ORF in 
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pFN21A was purchased from Promega. eIF4EBP1–HaloTag human ORF in pFN21A was 
purchased from Promega. pFN29K His6HaloTag T7 Flexi vector and the Flexi System 
cloning kit were purchased from Promega. pHA–eIF4E (Plasmid #17343) was purchased from 
Addgene. All data was analyzed using GraphPad Prism version 6.0c for Mac OS X (GraphPad 
Software, www.graphpad.com).  
2.5.1.3  GENERAL PEPTIDE SYNTHESIS 
4E–BP1 peptide (Gly49−Asn64) was synthesized on a 0.2–mmol scale in a 20–mL fritted 
syringe using MBHA Rink amide resin (0.4 mmol/g resin, average). In brief, the resin was 
initially washed with DMF (3  10 mL) and CH2Cl2 (3  10 mL) and allowed to swell for 30 min 
at 25 C in 1:1 DMF/CH2Cl2. Fmoc groups were removed following addition of a 20% 
piperidine/DMF solution (10 mL) and gentle agitation for 20 min at 25°C. After each Fmoc 
deprotection and amino acid couplings, the resin was thoroughly washed with NMP (3  10 mL), 
CH2Cl2 (3  10 mL), and DMF (3  10 mL). Amino acid couplings were performed by addition 
of amino acid (0.8 mmol) pre–activated with HBTU (0.72 mmol), N,N–diisopropylethylamine 
(1.28 mmol) in NMP (4 mL), and agitation for 2 h at 25 °C. Upon completion of the sequence, 
the N–terminus was acetylated, and the peptide was cleaved from the resin using 
TFA/thioanisole/triisopropylsilane/water (90:0.4:0.4:0.2) for 5 h at 25 °C. The resulting solution 
was added to glacial ether (~200 mL) for peptide precipitation. The precipitates were then 
centrifuged, dissolved in ACN–water mixture, and purified via RP–HPLC. Fractions containing 
the desired peptide were confirmed via Q–TOF HPLC–MS, lyophilized, acetic acid exchanged, 
lyophilized again, and then dissolved in 33% DMF/H2O. Peptide stock concentrations were 
quantified via amino acid analysis. 
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2.5.2 SYNTHETIC METHODS 
Synthesis of 2–(4–(6–methyl–1,2,4,5–tetrazin–3–yl)phenyl)acetic acid 
 
 
 
The synthesis was adapted from that reported1-2. In a 5–mL pressure–resistant vial, 2–(4–
cyanophenyl)acetic acid (80.6 mg, 0.5 mmol) was dissolved in acetonitrile (260 L, 5 mmol). 
Fresh Ni(OTf)2 (90.9 mg, 0.5 mmol) and anhydrous hydrazine (800 L, 25 mmol) were 
subsequently added. The vial was then flushed with nitrogen and sealed, and the reaction was 
heated to 60 °C. After 24 h, the reaction was cooled to 25 C and transferred to a 1–L beaker. In 
a separate beaker, NaNO2 (690 mg, 10 mmol) was dissolved in H2O (10 mL). The resulting 
NaNO2 solution was then slowly added to reaction, followed by slow addition of 1M HCl, during 
which the solution turned bright red/pink in color and gas evolved from reaction. Addition of 1M 
HCl was continued until the gas stopped evolving from the solution and the pH remained at 3. 
(Caution! This step generates a large amount of toxic nitrogen oxide gas and should be 
performed in a well–ventilated fume hood.) The reaction mixture was extracted with CH2Cl2, 
washed brine, and dried with Na2SO4. The solvent was removed in vacuo, and the resulting 
residue was purified by chromatography (10% MeOH/CH2Cl2) on silica gel to afford 1 in 48% 
yield. 1H NMR (500 MHz, CDCl3, 293K): δ 8.51 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 
3.73 (s, 2H), 3.05 (s, 3H).  
 
OH
O
N
N CH3
1. NH2NH2, 5% Ni(OTf)2
2. NaNO2, 1M HCl
+
OH
O
N
N
N
N
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Synthesis of R–NHS. To a 10–mL round–bottom flask was added, R1–3–carboxylic acid (0.15 
mmols), N,N’–disuccinimidyl carbonate (0.16 mmols), N,N–diisopropylethylamine (0.3 mmols), 
and CH2Cl2 (5 mL). The resulting mixture was then stirred for 4 h at 25 C. The reaction was 
quenched with water, and organic layer was washed with brine and dried with Na2SO4. The 
solvent was removed in vacuo, and the resulting R1–3–NHS was used without further 
purification. 
 
Synthesis of R–Boc. To a 10–mL round–bottom flask was added, R1–3–NHS (0.11 mmols), N,N–
diisopropylethylamine (0.43 mmols), O–(2–Aminoethyl)–O′–[2–(Boc–amino)ethyl]hexaethylene 
glycol (0.11 mmols) and CH2Cl2 (4 mL). The resulting mixture was then stirred overnight at 25 
C. The solvent was removed in vacuo, and the resulting residue was dissolved in DMSO and 
water and purified via RP–HPLC. R1–Boc: HRMS (ESI+) calcd for 694.3823, found 595.2 
[M+H–Boc]. R2–Boc: HRMS (ESI+) calcd for 680.3745, found 681.3819 [M+H]. R3–Boc: 
HRMS (ESI+) calcd for 548.3309, found 449.1 [M+H–Boc]. 
 
Synthesis of R–NH2. To a 10–mL round–bottom flask was added, R1–3–Boc (0.05mmols) and 
TFA (10 mL). The resulting mixture was stirred for 2 h at at 25 C. TFA was then removed in 
vacuo overnight . The resulting R1–2–NH2 was used without further purification. 
 
Synthesis of R–HT. To a scintillation vial was added, R1–3–NH2 (0.05 mmols), 6–chlorohexanoic 
acid (0.2 mmols), EDC (0.2 mmols), N,N–diisopropylethylamine (0.4 mmols), and CH2Cl2 (5 
mL). The solvent was removed in vacuo, and the resulting residue was dissolved in DMSO and 
water and purified via RP–HPLC. 
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Biotin–PEG7–HT ligand. HRMS (ESI+) calcd for 726.3640, found 727.3721 [M+H]. 1H NMR 
(400 MHz, DMSO–d6, 293K): δ 4.30 (dd, J = 7.7, 5.0 Hz, 1H), 4.16 – 4.07 (m, 1H), 3.61 (t, J = 
6.6 Hz, 2H), 3.50 (s, 25H), 3.38 (t, J = 5.9 Hz, 4H), 3.18 (q, J = 5.8 Hz, 4H), 3.09 (dt, J = 10.3, 
5.5 Hz, 1H), 2.81 (dd, J = 12.4, 5.1 Hz, 1H), 2.57 (d, J = 12.8 Hz, 1H), 2.06 (td, J = 7.3, 2.1 Hz, 
4H), 1.76 – 1.18 (m, 12H). 
 
mTet–PEG7–HT ligand. HRMS (ESI+) calcd for 712.3563, found 713.3648 [M+H]. 1H NMR 
(500 MHz, DMSO–d6, 293K): δ 8.39 (d, J = 8.2 Hz, 2H), 8.24 (t, J = 5.7 Hz, 1H), 7.83 (t, J = 5.7 
Hz, 1H), 7.54 (d, J = 8.2 Hz, 2H), 3.61 (t, J = 6.4 Hz, 2H), 3.57 (s, 1H), 3.53 – 3.47 (m, 24H), 
3.43 (t, J = 5.7 Hz, 2H), 3.38 (t, J = 5.9 Hz, 3H), 3.24 (q, J = 5.7 Hz, 2H), 3.18 (q, J = 5.9 Hz, 
2H), 2.99 (s, 3H), 2.06 (t, J = 7.3 Hz, 2H), 1.69 (h, J = 6.6 Hz, 3H), 1.49 (p, J = 7.7 Hz, 3H), 
1.41 – 1.29 (m, 3H). 
 
 
Alkyne–PEG7–HT ligand. HRMS (ESI+) calcd for 580.3127, found 581.3277 [M+H]. 1H NMR 
(500 MHz, DMSO–d6, 293K): δ 2.40 – 2.34 (m, 24H), 2.30 (t, J = 6.4 Hz, 2H), 2.28 (dd, J = 5.5, 
2.8 Hz, 4H), 2.10 (q, J = 5.6 Hz, 4H), 1.20 (ddd, J = 9.1, 5.5, 2.3 Hz, 2H), 1.14 (dd, J = 7.8, 5.6 
Hz, 2H), 1.02 (t, J = 2.6 Hz, 1H), 0.96 (t, J = 7.4 Hz, 2H), 0.52 (p, J = 6.8 Hz, 2H), 0.38 (p, J = 
7.5 Hz, 2H), 0.21 (p, J = 7.6, 7.0 Hz, 2H). 
 
Native 4E–BP1 – CH3CO–GTRIIYDRKFLMECRN–NH2 
HRMS (ESI+) calcd for 2055.0506, found 2056.0606 [M+H].  
 51 
 
Alkynyl 4E–BP1 – &GTRIIYDRKFLMECRN–NH2, & = 5–pentynoic acid 
HRMS (ESI+) calcd for 2080.10, found 2081.11 [M+H] 
2.5.3  PROTEIN EXPRESSION AND PURIFICATION 
HaloTag–eIF4E. Human eIF4E cDNA was cloned from pHA–eIF4E with engineered Sgf1 and 
PmeI restriction enzyme sites. The resulting product was ligated into a pFN29K vector via built–
in Sgf1 and PmeI restriction sites. Overnight culture of E. coli carrying pFN29K eIF4E was 
diluted (1:400) into LB media, and incubated at 37 °C until an OD600 of 0.6 was achieved. The 
resulting culture was induced with 0.5 mM IPTG overnight at 20 °C. Cells were pelleted, re–
suspended in lysis buffer (50 mM phosphate buffer, 100 mM NaCl, 0.5 mM PMSF, 0.5 mM 
EDTA, 5 mM DTT, 5 mM β–mercaptoethanol, 0.5% Tween–20), and lysed via ultrasonication. 
The resulting lysate was centrifuged at 25,000 RPM for 1 h at 4 °C. The supernatant was 
collected, incubated with m7GDP agarose resin and gently agitated on a rocker at 4 °C for 1 h. 
The resin was washed twice with wash buffer (50 mM phosphate buffer, 100 mM NaCl, 5 mM 
DTT), and eluted with 10 mM m7G in wash buffer. The protein was dialyzed overnight in wash 
buffer containing 2 mM DTT, concentrated in a 50–mL conical concentrator, and quantified via 
the Bradford assay. 
 
HaloTag–4E–BP1. eIF4EBP1–HaloTag human ORF in pFN21A was transferred into the 
pFN29K His6HaloTag T7 Flexi vector using the Flexi System. Overnight culture of E. coli 
carrying pFN29K 4E–BP1 was diluted (1:400) into LB media, and incubated at 37 °C until an 
OD600 of 0.6 was achieved, and induced with 0.5 mM IPTG for 3 h. Cells were pelleted, re–
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suspended in lysis buffer (50 mM phosphate buffer, 100 mM NaCl, 0.5 mM PMSF, 5 mM DTT, 
1% Triton–100), and lysed via ultrasonication. The resulting lysate was centrifuged at 25,000 
RPM for 1 h at 4 °C. The supernatant was collected and incubated with Ni–NTA resin for 30 min 
@ 4°C. The resin was then washed with wash buffer (50 mM phosphate buffer, 100 mM NaCl, 2 
mM DTT), and eluted with increasing concentrations of imidazole (10−500mM). The protein 
was dialyzed overnight at 4°C in wash buffer and further purified by FPLC on a S200 column. 
Protein quantification was determined via the Bradford Assay.  
 
HaloTag–eIF4G. eIF4GI–HaloTag human ORF in pFN21A was purchased from Promega 
eIF4GI isoform 1 cDNA was purchased from Promega. A C–terminal 5His tag was 
subsequently added by ligating annealed oligos encoding for the 5His tag into the PmeI 
restriction site. HEK293T cells at 60% confluence in a 15–cm plate were transfected with 15 ug 
of purified DNA using linear PEI 25,000MW (Polysciences, Inc.); media was changed 18 h after 
transfection. 24 h later, media was aspirated, cells were washed once with 25 mL ice–cold 1X 
PBS, and then harvested by scraping into 3 mL of 1X TBS pH 7.5 containing 7 g/mL pepstatin, 
5 g/mL leupeptin, and 10 g/mL aprotinin. Cells were lysed by passing through a sterile, 28.5–
gauge syringe (5) on ice, and lysates were cleared by centrifugation at 18,000g for 10 min at 4 
C. Cleared lysates were incubated end–over–end with pre–washed Ni–NTA resin for 2 h at 4 
C, then washed 3 with lysis buffer for 30 min each. ‘Semi–purified’ His–HaloTag–eIF4G was 
eluted with 500 mM imidazole in 1X TBS pH 7.5, before dialyzing overnight at 4 C. Protein 
quantification was determined via the Bradford Assay.  
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Mutagenesis. The following oligonucleotides were used to create point mutations in the 
HaloTag–4E–BP1 coding sequence using site–directed mutagenesis. cDNA sequences were 
confirmed by Sanger sequencing.  
Y54A, Forward: 5’– GGGAGGTACCAGGATCATCGCTGACCGGAAATTCCTG–3’; 
Reverse: 5’– CAGGAATTTCCGGTCAGCGATGATCCTGGTACCTCCC–3’ 
L59A, Forward: 5’–CTATGACCGGAAATTCGCGATGGAGTGTCGGAACTCAC–3’; 
Reverse: 5’–GTGAGTTCCGACACTCCATCGCGAATTTCCGGTCATAG–3’ 
M60A, Forward: 5’–CTATGACCGGAAATTCCTGGCGGAGTGTCGGAACTCAC–3’; 
Reverse: 5’– GTGAGTTCCGACACTCCGCCAGGAATTTCCGGTCATAG–3’ 
L59A/M60A, Forward: 5’– 
CTATGACCGGAAATTCGCGGCGGAGTGTCGGAACTCAC–3’; Reverse: 5’– 
GTGAGTTCCGACACTCCGCCGCGAATTTCCGGTCATAG–3’  
2.5.4  BIOCONJUGATION METHODS 
Biotinylation of eIF4E, eIF4G and 4E–BP1. HaloTag–eIF4E, –eIF4G, and –4E–BP1 were 
biotinylated by addition of Biotin–PEG7–HT ligand (20 equiv) in reaction buffer (50 mM 
phosphate buffer, 100 mM NaCl, pH 7.4, 5 mM DTT, 10% glycerol) and incubation overnight at 
4 °C. The resulting mixture was concentrated in wash buffer (50 mM phosphate buffer, 100 mM 
NaCl, 5 mM DTT), buffer exchanged with wash buffer (6  20 mL), and quantified via the 
Bradford assay. Successful biotinylation was confirmed via Western blot with streptavidin–HRP. 
 
mTet and Alkyne Labeling of 4E–BP1. HaloTag–4E–BP1 was labeled by addition of mTet–
PEG7–HT ligand or Alkyne–PEG7–HT ligand (20 equiv) in reaction buffer (50 mM phosphate 
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buffer, 100 mM NaCl, pH 7.4, 5 mM DTT, 10% glycerol) and incubation overnight at 4 °C. The 
resulting mixture was concentrated again in wash buffer (50 mM phosphate buffer, 100 mM 
NaCl, 2 mM DTT), buffer exchanged with wash buffer (6  20 mL), and quantified via the 
Bradford assay. Successful labeling was confirmed via click chemistry with a click handle–
labeled rhodamine. 
 
HRP–N3. HRP–N3 was prepared following an established procedure and stored at 4°C in 
phosphate buffer (50 mM, pH 7.4).4 Successful introduction of azide was confirmed via reaction 
with Rhod–alkyne  
 
HRP–TCO.5 HRP (10 mg) was dissolved in phosphate buffer (50 mM, pH 7.4; 2 mL). TCO–
PEG4–NHS (20 equiv in DMSO) was subsequently added, and the reaction was gently agitated 
overnight at 4 °C. The resulting solution was concentrated and buffer exchanged with phosphate 
buffer. Successful HRP modification was confirmed via reaction with Rhod–mTet (Figure S2). 
 
CuAAC condition. TBTA (0.1 μL of 50 mM stock in DMSO, 0.5 mM final), CuSO4 (0.5 μL of 2 
mM stock in H2O, 0.1 mM final), and HRP–N3 (0.1 μL of 50 μM stock in phosphate buffer (pH 
7.4), 0.5 μM final) were diluted in phosphate buffer (pH 7.4) and agitated gently in a vial. 
Sodium ascorbate solution (0.5 μL of 100 mM stock in H2O, 5.0 mM final) was freshly made 
prior to use and added to initiate the CuAAC reaction. The reaction mixture (10 μL) was then 
added to assay wells, covered with plate–sealing tape, and agitated at 25 °C for 2 h. For the 
validations of HRP–N3, alkynyl 4E–BP1 peptide, and ALK–4E–BP1, 1 μM of alkynyl–
rhodamine, azido–rhodamine, and azido–rhodamine, respectively, were incubated with the same 
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TBTA–CuAAC conditions. THPTA ligand driven CuAAC conditions were followed as 
documented1. 
2.5.5  PPI CAT–ELCCA PROTOCOL (384–WELL FORMAT) 
Buffer A: 50 mM Phosphate Buffer (pH 7.4), 100 mM NaCl, 0.01% Tween–20, 2 mM DTT 
Buffer B: 50 mM Phosphate Buffer (pH 7.4) 
1. Immobilization of biotin–eIF4E (10 μL of 50 nM in Buffer A) 
a. POS Ctrl: add Buffer A (10 μL) 
b. NEG Ctrl: add biotin–eIF4E (10 μL) 
c. Cover the wells with plate–sealing tape 
d. Overnight incubation (4 °C) 
2. Remove well contents 
3. Wash the wells with Buffer A (3  50 μL) 
a. Incubate for 5 min between each wash 
4. PPI incubation 
a. Ctrls (POS & NEG): Add mTet 4E–BP1 (5 μL of 8 nM in Buffer A), dilute to 10 
μL with Buffer A 
b. Inhibitor incubations (Titrations) 
i. Inhibitors diluted to varying concentrations in Buffer A 
ii. Add inhibitor samples (5 μL), and then add mTet–4E–BP1 (5 μL of 8 nM 
in Buffer A) 
c. Cover the wells with plate–sealing tape 
d. Incubate at 4 °C for 60 min 
 56 
5. Remove well contents 
6. Wash the wells with Buffer A (3  50 μL) 
a. Incubate for 5 min between each wash 
7. Click chemistry with TCO–HRP (10 μL of 1 μM in Buffer A) 
a. Cover the wells with plate–sealing tape 
b. Incubate at 25 °C for 1 h 
8. Wash the wells with Buffer A (3  50 μL) 
a. Incubate for 5 min between each wash 
9. Wash the wells with Buffer B (3  50 μL) 
a. Incubate for 5 min between each wash 
10. For chemiluminescence detection: 
a. Add 30 μL SuperSignal West Pico Chemiluminescent Substrate (prepared 
following kit instructions) 
2.5.6  PEPPI CAT–ELCCA PROTOCOL 
Buffer A: 50 mM Phosphate Buffer (pH 7.4), 100 mM NaCl, 0.01% Tween–20, 2 mM DTT, 
0.08mg/mL bovine serum albumin 
Buffer B: 50 mM Phosphate Buffer (pH 7.4) 
 
1. Immobilization of biotin–eIF4E (10 μL of 50 nM in Buffer A) 
a. POS Ctrl: add Buffer A (10 μL) 
b. NEG Ctrl: add biotin–eIF4E (10 μL) 
c. Cover the wells with plate–sealing tape 
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d. Overnight incubation (4 °C) 
2. Remove well contents 
3. Wash the wells with Buffer A (3  50 μL) 
a. Incubate for 5 min between each wash 
4. Peptide–protein incubation 
a. Ctrls (POS & NEG): Add alkynyl 4E–BP1 (10 μL of 250 nM in Buffer A) 
b. Inhibitor incubations (Titrations) 
i. Dilute the inhibitors to desired concentrations in Buffer A 
ii. Add inhibitor samples (5 μL), and then add alkynyl 4E–BP1 (5 μL of 500 
nM in Buffer A) 
c. Cover the wells with plate–sealing tape 
d. Incubate at 4 °C for 120 min 
5. Remove well contents 
6. Wash the wells with Buffer A (3  50 μL) 
a. Incubate for 5 min between each wash 
7. Click chemistry with N3–HRP (10 μL of 0.5 μM in Buffer B, see BIOCONJUGATION 
METHODS) 
a. Cover the wells with plate–sealing tape 
b. Incubate at 25 °C for 2 h 
8. Wash the wells with Buffer A (3  50 μL) 
a. Incubate for 5 min between each wash 
9. Wash the wells with Buffer B (3  50 μL) 
a. Incubate for 5 min between each wash 
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10. For chemiluminescence detection: 
a. Add 30 μL SuperSignal West Pico Chemiluminescent Substrate (prepared 
following kit instructions) 
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CHAPTER 3     HIGH-THROUGHPUT SCREENING CAMPAIGN TARGETING THE 
CAP-DEPENDENT TRANSLATION INITIATION  
 
3.1 4EGI–1 DISCOVERY & VALIDATION 
4EGI–1 (Figure 16A) was the product of a HTS campaign by Moerke et al3 using a 
fluorescence polarization or anisotropy (FP) assay. FP is a very common mix–and–read HTS 
technique. As of January 2018, there were approximately 2,700 FP assays reported against nearly 
1,700 different protein, enzyme, RNA, and receptor targets. The fundamental principle of FP is 
the inverse relationship between the polarized fluorescence and its molecular rotation. Polarized 
 
Figure 16. 4EGI-1. A) 4EGI–1 structure, 2–aminothiazole is highlighted in red; B) schematic of the HTS 
FP assay used by Moerke et al. and peptide probe sequence 
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light source excites the fluorescence probe, the emission fluorescence is filtered parallel and 
perpendicular to the excitation plane, and measured (Figure 16B, modified4). In FP assays 
designed for PPI HTS campaigns, this fluorescence probe is generally a fluorophore–labeled 
peptide composed of the hotspot binding sequence. In absence of a binding event, these 
fluorophore peptides have high molecular rotation (θ), and therefore, will yield depolarized 
emission signal (parallel ~ perpendicular polarized fluorescence); in binding to a protein and 
undergoing a significant gain in the molecular weight, the fluorophore–peptide/protein complex 
have much lower molecular rotation and will yield increased polarized emission (parallel >> 
perpendicular fluorescence).  
In the specific design of the FP assay that led to the discovery of 4EGI–1, Moerke et al. 
did not use the native peptide sequence extracted from neither mammalian eIF4G nor 4E–BP1, 
but designed a sequence modified from yeast CAF203, KYTYDELFQLK, with modest binding 
affinity of 150nM. The authors did not elaborate further on their sequence choice, but peptide 
aggregation may have forced the investigators to make subtle amino acid mutations5. For weaker 
PPIs, FP assays may require proteins and/or peptides above soluble and aggregate–free 
concentrations to observe a robust S/B and suitable Z’ factors. For the stronger PPIs, the FP 
assay may require proteins and/or peptides at a concentration far past the binding affinity, and 
significantly decrease the likelihood of discovering a hit compound strong enough to disrupt the 
PPI in the HTS campaign. For instance, the reported affinities of mammalian native 4E–BP1, 
eIF4GI, and eIF4GII canonical binding motif are very strong, below 50 nM by isothermal 
calorimetry6; an optimal HTS FP assay designed against these interactions would require much 
less than 50 nM of fluorescently–labeled peptides, or suffer from a drastically reduced chances 
of discovering a hit compound through screening. 4EGI–1 HTS campaign used a peptide that 
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yielded binding affinity of 3 μM and had greatly increased their chances of obtaining a hit 
compound. FP assays are also susceptible to the HTS compound interference through 
fluorescence quenching and autofluorescence7. The extent of chemical interference can be 
mitigated by designing, optimizing, and running two sequential (or simultaneous) FP assays with 
two different fluorophores; a hit compound confirmed by the two FP assays is likely to be a true 
positive. Despite the listed limitations, FP assays remain a powerful and heavily utilized 
technique in most HTS campaigns due to their low cost and simplicity. 
4EGI–1 binding to eIF4E was characterized and confirmed through nuclear magnetic 
resonance (NMR) experiments. NMR is rarely used in large HTS campaigns due to its low 
throughput, the extensive amounts of reagents required, and the often-required nuclei labeling of 
proteins. In fact, NMR confirmation of 4EGI–1 binding required greater than 200 µM of highly 
soluble and well–behaved mammalian eIF4E; however, mammalian eIF4E is notoriously 
insoluble and susceptible to aggregation and precipitation, and had to be tagged with a solubility 
enhancement tag, GB18, for the NMR characterization. Despite the limitations, NMR boasts very 
high sensitivity, reveals extensive molecular details about the PPI, and is extremely useful for 
evaluating the potential “ligandability9” of the PPI. HTS NMR is a popular technique for 
fragment–based drug discovery to build the potential agonist/antagonist, and has shown success 
in building MCL–1 inhibitors1, 10-11 and Smac/DIABLO PPI inhibitors. HTS NMR is a powerful 
alternative to the cases in which the traditional HTS campaigns have failed or as a secondary 
confirmation assay. GB1–eIF4E titrations to 4EGI–1 showed 25 µM ± 11µM binding affinity, 
suggesting that it acted as a 4E–BP mimetic compound, and further in cellulo eIF4E pull–down 
experiments showed a successful dose–dependent inhibition of eIF4G–eIF4E interaction and 
stimulation of the eIF4E–4E–BP1 interaction. 
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Despite the initial success of 4EGI–1, rising evidence suggests that the anti–proliferative 
effects of 4EGI–1 may not solely be due to the inhibition of the eIF4E PPIs. In addition to the 
inconsistent binding mechanism of action, 4EGI–1 has shown similar IC50 in both in vitro assays 
(25 µM) and cell apoptosis assays (1 – 30 µM) and strengthens the possibility that 4EGI–1 
induces non–specific interactions in its mechanism of action. 4EGI–1 treatments also induced 
phenotypes inconsistent with previous eIF4E knockouts and knockdowns, from inhibiting 
eIF4E–independent protein translation14-15 to anti–proliferative activities in multiple myeloma16-
18 and in leukemia. Furthermore, its role as a 4E–BP mimetic was later corrected when 4EGI–1–
eIF4E protein complex was crystallized and showed allosteric binding mechanism of action. 
4EGI–1 also contain structural motifs that are commonly classified as “pan–assay interference 
compounds” or PAINS. Specifically, the 2–aminothiazole motif on 4EGI–1 (Figure 16A) has 
documented metabolic reactivity to yield toxic and protein reactive metabolites26. Although a 
recent study found that the presence of a specific PAINS motif does not accurately dictate the 
whole molecule as a PAINS27, the current 4EGI–1 studies appear to be insufficient to disprove 
this possibility and dampers the enthusiasm of 4EGI–1 as a successful chemical probe and 
potential clinical candidate. 
3.2 4E1RCAT DISCOVERY AND VALIDATION 
In 2011, Cencic et al.27 reported a HTS campaign that discovered a new eIF4E PPI 
inhibitor, 4E1RCat (Figure 17A) using a time resolved fluorescence resonance energy transfer 
(TR–FRET) assay (Figure 17B). FRET is another popular mix–and–read HTS assay. As of
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January 2018, there were approximately 1,600 FRET assays reported against nearly 1,200 
different protein, enzyme, and receptor targets. FRET exploits the transfer of non–radiative 
energy between a donating fluorophore (donor) to the accepting fluorophore (acceptor) within 
limited distance (often to less than 10 nm). In HTS FRET, a protein pair is labeled with a donor 
and an acceptor fluorophore through chemical conjugation or fluorescently–tagged antibodies. 
Upon interaction, depending on the biophysical orientations of the fluorophore pairs, the 
excitement of the donor will result in acceptor emission. Its strengths, like FP assays, are its easy 
implementation, high–throughput, and relative low cost. However, FRET is not without its 
limitations: 1) multiple combinations of donor/acceptor fluorophore pairs need to be explored for 
 
Figure 17. 4E1RCat. A) 4E1RCat structure, promiscuous scaffold highlighted in red; B) schematic of the 
HTS TR–FRET assay used by Cencic et al1, and the eIF4G1 region used in the screen 
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the protein pair to optimize signal and protein complex stability, 2) the biophysical orientations 
of the two fluorophores bound to their respective partners on the protein complex must be within 
10 nm and may require different protein constructs to move the fluorophore from N–terminus to 
C–terminus or vice versa. And as with most fluorescence–based assays, FRET is highly 
susceptible to quenching and autofluorescence by the library compounds and assay 
buffer/media28. In addition, wide donor emission and acceptor excitation spectra could allow 
nonspecific background fluorescence and drastically reduce the assay sensitivity and robustness. 
TR–FRET addresses the interferences by replacing the donor fluorophores with rare earth metals 
cryptates bound to Europium or Terbium. These improved donor fluorophores have long 
luminescence half–life (up to 1500 µs29), allowing a time–delay between the donor excitation 
and measuring the acceptor emission. The compound/buffer/media interference, and the 
nonspecific acceptor excitations all have very rapid fluorescence decay and are eliminated by the 
actual acceptor emission measurement. Furthermore, the rare earth metal cryptates have greater 
proximity limit, in most cases up to 20 nm, and have greater tolerance for biophysical orientation 
errors of protein–protein complex.  
Cencic et al. chose Eu–W1024–labeled anti–6x–His antibody as the donor fluorophore to 
recognize His6–tagged eIF4E and allophycocyanin tagged anti–GST IgG antibody as the 
acceptor fluorophore to recognize GST–tagged eIF4GI517–606 with 50 µs time delay. The assay 
was designed, optimized, and screened, with reported average Z’ factor above 0.6 and S/B above 
10. The donor/acceptor pairs for TR–FRET are ever–expanding, and various assay 
optimizations30 are continuously reported and edited for greater robustness and larger 
applications. 
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The eIF4G1 region chosen for this TR–FRET HTS campaign is questionable, as the 
K517 – L606 motif is not part of the canonical binding motif to eIF4E, and the specific purpose 
and structure of this region remains unknown (could also be a mistake in the manuscript). 
Although 4E1RCat claims to be a 4E–BP mimetic compound, the protein–4E1RCat complex 
remains unsolved; In addition, a large substructure of 4E1RCat has also been shown to inhibit 
the p300−CBP PPI, E. coli heptosyl transferase WaaC, cholesterol accumulation, the MurG 
glycosyltransferase, mPGES–1 and PTPMT131-32, and could be a very promiscuous ligand. Thus, 
4E1RCat, like 4EGI–1, remains an imperfect chemical probe. 
3.4 HTS PPI CAT–ELCCA 
3.4.1  PPI CAT–ELCCA AND AGGREGATORS 
In addition to the previously demonstrated compatibilities of cat–ELCCA with 
fluorescent molecules and fluorescence quenchers, PPI cat–ELCCA also tolerated up to 10% 
DMSO for compound dosing. Subsequently, the known aggregators that are littered within 
screening libraries32 were assayed in PPI cat–ELCCA. These aggregate–forming molecules, 
quercetin, benzyl benzoate and Congo Red (Figure 18A), were tested at 12.5, 25 and 50 M; of 
these, Congo Red was found to inhibit the assay (Figure 18B) in a dose-dependent manner. The 
removal of detergent Tween–20 from the assay buffer eliminated this dose–responsive nature of 
Congo Red (Figures 18C, D). Furthermore, as observed from assaying the linear peptides at 
high concentrations, Congo Red in absence of Tween–20 exhibited high increase in the 
chemiluminescence signal. Thus, this spike in the PPI cat–ELCCA signal is associated with 
aggregators or at compound doses in which the chemical induces protein aggregation and 
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precipitation. Congo Red is likely a real, yet non–specific inhibitor of the PPI and the assay, as 
evidenced by its Hill slope < –2 similar to 4EGI–1 and 4E1RCat.  
 
3.4.2  HTS SCREENING 
3.4.2.1  FRAGMENT LIBRARIES 
To support the use of PPI cat–ELCCA in high–throughput inhibitor discovery, the assay was 
miniaturized to screen against the eIF4E−4E–BP1 interaction. Importantly, the assay performed 
excellently with a measured Z’ factor of 0.66, S/B ratio of 23 and signal–to–noise (S/N) ratio of 
>10,000 (Figure 19A). Both aspiration-based (Biotek ELX 405) and centrifugation-based 
(BlueCatBio BlueWashers) plate washers were evaluated during the assay miniaturization; 
despite the greater washing capacity of the centrifugation-based plate washer – as evidenced by 
 
Figure 18. Effect of aggregators on PPI cat-ELCCA. Aggregator characterization of PPI cat–ELCCA. A) 
Established aggregators, B) Effect of aggregators, C,D) Dose–dependence of Congo Red in the presence 
and absence of 0.01% Tween–20, respectively. All experiments were conducted in triplicates (n=3) and 
shown as the mean ± SD. 
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complete elimination of residual liquid in the wells post-wash – the edge wells consistently 
yielded lower signal output. Biotek ELX 405 washer often suffered from technical difficulties 
(clogged pins, uneven liquid distribution, and etc.), but these problems were easily addressable. 
Thus, PPI cat-ELCCA was miniaturized for HTS campaign using the aspiration-based washer. 
HTS potential is generally determined by the Z’ factor, and it is the most important statistical 
parameter; assays exhibiting Z’ factors of  0.5 are regarded as suitable assays to conduct a HTS 
campaign. As additional characterization, a small collection of ~3,000 fragment molecules were 
screened at high concentrations (400 M−1 mM). The required high dosage using this library is 
often accompanied by an increase in the compound interference in biochemical assays33-34 and 
are limited to using low–throughput biophysical methods. Although no hit compounds were 
identified (Figure 19B), the assay performed well with Z’ factors ranging between 0.44−0.67. 
With respect to compound interference, few compounds had yielded luminescence signals higher 
than the negative control; based on the previous results with Congo Red (aggregator) in the 
absence of detergent, these compounds likely induced aggregation or had crashed out of solution 
 
 
Figure 19. PPI cat-ELCCA HTS Characterization. A) PPI cat–ELCCA exhibits Z’ factor greater than 
0.65, B) preliminary screening with fragment library compounds 
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due to insolubility. Nonetheless, based on this and the presented preliminary data, PPI cat–
ELCCA was employed in further HTS campaign to discover the chemical probes for the eIF4E 
PPIs. 
3.4.2.2  NPE LIBRARIES 
 PPI cat–ELCCA was used to screen the natural product extract library (Figure 20). CCG 
NPEs are derived from a large collection of cyanobacteria and sponges from all over the globe. 
In brief, pure strains of microbes are isolated from these sediments through carefully 
monitored conditions, and new natural product molecules are extracted for analysis in HTS 
campaigns. The active fraction must then be subjected to iterative fractionation and screening 
process to narrow down to the active compound, which will then require full chemical 
characterization and re-testing. Upon successful identification and characterization of the active 
 
Figure 20. The primary screening of the NPE library. Z’ = 0.62. HTS statistics of the NPE library using 
PPI cat–ELCCA, representative CRCs of validated hits normalized to the assay controls. The CRC data 
was collected in duplicates (n=2). 
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compounds, the strains responsible for its production are phylogenetically characterized. CCG 
NPEs have been utilized successfully to discover novel activities of known natural products32, 35; 
however, it is underutilized in HTS campaigns due to the high false positive hit rates and the 
labor-intensive identification of the active compounds36-37. The fluorescence and quenching 
interferences from the NPE library can be somewhat mitigated by using red–shifted dye or 
fluorophores since the NPEs may interfere significantly more with blue–shifted fluorescence 
wavelengths35.  The potential reactive metabolites could be neutralized through specific chemical 
conditioning, and pre–fractionation drastically reduces sample complexity for easier 
identification of the active compound. Employing quantitative HTS and utilizing compound 
titrations to prioritize identifications of active fractions can dramatically improve lead validation 
as well1. Clearly, the NPE library requires a robust, sensitive assay to obtain high confidence 
screening data in midst of the complex chemical mixtures. PPI cat–ELCCA is an ideal assay that 
could identify the untapped potential inhibitors of this underutilized library. 
The primary campaign identified 340 hits with greater than 50% inhibition (1.00%), and 
72 hits were validated (21.2%). To prioritize the fractions for further fractionations, 
concentration response curves (CRC) were acquired from 38 validated hits; of these, 18 samples 
(47.4%) appeared dose-responsive with hill slopes ranging from –0.5 to –2.0, suggesting a ligand 
binding mechanism of action. The 18 samples are pending re–isolation from their respective 
cultures by the Sherman group. The successful NPE library screening campaign suggests that 
PPI cat–ELCCA is a powerful tool in screening complex mixtures. 
3.4.2.3  ELI LILLY BIOLOGY INTERROGATION COMPOUND LIBRARY 
 As part of the Eli Lilly Open Innovation Drug Discovery program, the Garner group 
received their customized Biology Interrogation Compound (BIC) library to screen against the 
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eIF4E–4E-BP1 interaction using PPI cat-ELCCA (Figure 21). The primary campaign against 
20,793 compounds identified 112 hits with greater than 10% inhibition (0.54%); CRC were 
obtained for 86 hits for confirmation, and 9 compounds were identified to be dose-responsive 
 
Figure 21. The primary screening of the BIC library. Z’ = 0.7. HTS statistics of the NPE library, and the 
representative CRCs of validated hits normalized to the assay controls. The CRCs were collected in 
duplicates (n=2) and shown as the mean ± SD. 
 
Table 2. Validated hits from the BIC library. The binding affinities were All experiments were conducted 
in duplicates (n=2). 
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(10.5%). Of these 9 compounds, 6 had elicited direct binding to eIF4E by SPR and are currently 
being investigated under collaboration with Eli Lilly (Table 2). 
3.5 CONCLUSION 
The HTS campaigns to discover potent small molecule inhibitors targeting the eIF4E 
interactions have remained elusive. Although both 4EGI-1 and 4E1RCat inhibitors successfully 
disrupt the eIF4E interactions, their chemical structures resemble PAINS and other known 
nonspecific binding motifs, and ultimately, are poor candidates for the therapeutic development. 
The HTS campaign using PPI cat-ELCCA to screen against the eIF4E interactions was 
advantageous over the previously attempted campaigns using FP and TR-FRET. First, PPI cat-
ELCCA screened against the more physiologically relevant full-length proteins that best 
mimicked the native eIF4E interactions instead of relying on the “hot spot”. Second, the catalytic 
amplification of PPI cat-ELCCA signal allowed for compound screening against 4 nM protein 
complex whereas the FP assay required more than 50 nM peptide-protein complex. Third, the 
low chemical interference of PPI cat-ELCCA allowed for high confidence screening in the novel 
chemical space of natural product extracts. Despite these incremental gains, ultimately, the small 
molecule drug discovery targeting the eIF4E interactions remain a work in progress, with 
extensive compound isolation and characterizations of the NPE hits and further compound 
explorations from the BIC library hits. However, novel HTS assay like PPI cat-ELCCA could be 
the paradigm shifting tool needed to succeed where the traditional assays have failed, and to 
breathe new life into the drug discovery campaigns of difficult, elusive PPI targets. 
3.6 HTS PPI CAT–ELCCA PROTOCOL (384–WELL FORMAT) 
HTS PPI cat–ELCCA Protocol (384–well format) 
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Buffer A: 50 mM Phosphate Buffer (pH 7.4), 200 mM NaCl, 0.01% Tween–20, 2 mM DTT 
Buffer B: 50 mM Phosphate Buffer (pH 7.4), 200 mM NaCl, 0.05% Tween–20 
Buffer C: 50 mM Phosphate Buffer (pH 7.4) 
*Pre–wash with and pre–dispense a dummy dispense (~half of the required volume, or less) 
 
1. Immobilization of biotin–eIF4E (10 μL of 50 nM in Buffer A) 
a. **Prime the tubing well** 
b. POS Ctrl (usually columns 23–24): add Buffer A (10 μL) 
c. NEG Ctrl (usually columns 1–2): add biotin–eIF4E (10 μL) 
d. Compound wells (usually columns 3–22): add biotin–eIF4E (10 μL) 
e. Cover the wells with plate–sealing tape. 
f. Spin down on centrifuge (1000xRPM, 1min, 4C) 
g. Overnight incubation (4 °C) 
h. **Thoroughly wash and clean the dispensing cassette with Buffer C, and then 
with water** 
2. Removing well contents 
a. Prime ELX405 with Buffer B & wash with Method #66 
b. Lay absorbent towel, smack the plates post wash (should see residual liquid 
leaving stains on the towel) 
c. Finish washing the rest of the plates in the exact same way prior to the next step 
3. PPI incubation of mTet 4E–BP1 (10 μL of 4nM in Buffer A) 
a. **Prime the tubing well** 
b. Add mTet 4E–BP1 (10 μL of 4 nM in Buffer A) to all the wells 
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c. Dispense the compounds 
d. Cover the wells with plate–sealing tape 
e. Spin down on centrifuge (1000xRPM, 1min, 4C) 
f. Incubate at 4 °C for 45 min  
4. Removing well contents 
a. Prime ELX405 with Buffer B & wash with Method #66 
b. Lay absorbent towel, smack the plates post wash (should see residual liquid 
leaving stains on the towel) 
c. Finish washing the rest of the plates in the exact same way prior to the next step 
5. Click chemistry with TCO–HRP (10 μL of 1 μM in Buffer A) 
a. **Prime the tubing well** 
b. Add TCO–HRP (10 μL of 1 μM in Buffer A) to all the wells 
c. Cover the wells with plate–sealing tape 
d. Spin down on centrifuge (1000xRPM, 1min, 4C) 
e. Incubate at RT for 45 min 
6. Removing well contents 
a. Prime ELX405 with Buffer B & wash with Method #66 
b. Lay absorbent towel, smack the plates post wash (should see residual liquid 
leaving stains on the towel) 
c. Finish washing the rest of the plates in the exact same way prior to the next step 
7. Final wash with Buffer C 
a. Prime ELX405 with Buffer C & wash with Method #66 
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b. Lay absorbent towel, smack the plates post wash (should see residual liquid 
leaving stains on the towel) 
c. Finish washing the rest of the plates in the exact same way prior to the next step 
8. chemiluminescence detection 
a. **Prime the tubing well** 
b. Add chemiluminescence substrate (25 μL of 1:1 mixture of black & white 
components of the chemiluminescence  substrates) to all the wells 
c. Stack the plates, from bottom up = 1,2,3,4,dummy 
9. Readout 
a. Load up the stacker with the plates, and start the data collection 
i. The protocol takes the focal adjustment from the first plate and keeps that 
constant throughout the rest of the plates 
ii. The protocol marks the gain from A2, and sets it to 60% for each plate 
3.7 EXPERIMENTAL 
 Plate washing was performed using a Biotek 405 ELX plate washer. Liquid handling 
was performed using a Multidrop Combi Reagent Dispenser (Thermo Scientific). All the 
compounds were dispensed using a Sciclone (Caliper) liquid handler with V&P pintool. The 
fragment library includes 2,668 fragments of MW 150−300 (Asinex) and 237 natural product–
like fragments (AnalytiCon Discovery). Asinex fragments were screened at 1 mM final 
concentration. AnalytiCon fragments were screened at 400 M final concentration. The NPE 
library compounds were screened at 0.5% DMSO final concentration, or at 200–fold dilution of 
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the stock. Chemiluminescence signal was detected using a PHERAstar plate reader using LUM 
plus module (BMG Labtech). 
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CHAPTER 4 DESIGN, DEVELOPMENT, AND CHARACTERIZATIONS OF 4E–BP1 
MIMETIC STAPLED PEPTIDES 
 
4.1 DRUG DISCOVERY: PEPTIDES TARGETING PROTEIN–PROTEIN 
INTERACTIONS2 
Peptides have gained significant interest in recent years despite their well–documented 
intrinsic flaws: poor chemical stability and oral availability, short circulating plasma half–life, 
solubility, and most prominently, low cell permeability. Extensive medicinal chemistry 
campaigns have addressed these flaws, from ‘piggy–backing’ onto the protein albumin and 
peptide macrocyclization to increase their effective half–life3, peptide acylation4 and peglyation5 
(both6) to increase solubility to bring their candidates closer to therapeutics. Besides the 
revolutionary discoveries and applications of insulin7, there are more than 60 peptide drugs that 
the US FDA had approved for treatments, more than 140 peptides in clinical trials, and far 
greater number in preclinical development (reviewed8-10).  
Constraining the conformational flexibility of a molecule to mimic the active compound 
structure reduces the entropic penalty of binding to improve affinity and selectivity11. Peptide 
macrocyclization, or peptide stapling, utilizes this concept in full and has garnered much 
attention in the recent decade as an innovative medicinal chemistry technique to increase peptide 
half-life, inhibitory potency, and cell permeability. The structured motifs isolated for peptide 
                                                 
2 As of July 2018, this work is under revision at Journal of American Chemical Society and titled “Probing the 
Importance of Folding Dynamics in the Design of Stapled Peptide Mimics of the Disordered Proteins 4E-BP1 and 
eIF4G”. Co-authors include: Gallagher, Erin (Co-first author, SPR and CD experiments); Menon, Arya (cell 
biology including eIF4E complex pulldown experiments); Mishra, Lauren (initial stapled peptide design and 
synthesis); Chmiel, Alyah (peptide synthesis); Mitchell, Dylan (flow cytometry) 
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design often retain their secondary structures even when it is converted to a peptide. Peptide 
stapling pre-forms or pre-positions the crucial amino acids to achieve low–energy barriers to 
adopt various secondary structures, such as α–helices, β–sheets, and β–hairpins. 
4.1.1 PEPTIDES 
Peptide mediated disruption of the eIF4E interactions have been in the works for 
decades12 since the canonical binding motifs of eIF4G and 4E–BP1 have been shown to bind to 
eIF4E13-14. Investigators have attempted to address the peptides’ poor permeability through 
fusion peptides containing cell penetrating peptides (CPP). Herbert et al. demonstrated that a 
peptide containing penetratin fused to the canonical eIF4E binding motif led to dose–dependent 
apoptosis, and that alanine mutations at key residues reduced and eliminated this bioactivity15. 
Similarly, Brown et al. attached the CPP tag TAT to their enhanced α–helicity eIF4G1 peptide to 
show a similar improved apoptotic cell death upon treatment16.  However, both studies showed 
strong evidence of apoptosis with their negative control CPP and required serum deprivation, 
which highlighted strong possibilities that the observed apoptosis could be due to nonspecific 
interactions of the CPPs. Alternative to using the CPPs, Ko et al. conjugated the 4E–BP1 
mimetic peptide to an agonist of gonadotropin–releasing hormone (GnRH). This fusion peptide 
exploited the GnRH receptors that are highly expressed in epithelial ovarian cancer17 to gain both 
target specificity and increased peptide permeability. This GnRH fused 4E–BP1 peptide 
successfully reduced the tumor burden in ovarian cancer mouse model compared to the saline 
treatment. Effectively, these studies demonstrated the therapeutic relevance of a cell permeable 
4E–BP1 or eIF4G mimetics and marked the eIF4E interaction as a possible therapeutic target 
using the emerging peptide stapling technologies.  
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4.1.2 ΑLPHA HELIX STAPLED PEPTIDES 
Many pathological PPIs18 are reliant on α–helix driven interactions, including that of the 
eIF4E PPIs. The canonical binding motifs of both 4E–BP1 and eIF4G bind and adopt a short α–
helical structure. The most well–established stapling strategies are through hydrocarbon stapling, 
lactamisation19-21,  Cu(I)–catalyzed azide–alkyne cycloaddition (CuAAC)22-27, or thioether 
stapling28-31 (Figure 22). In general, these strategies capitalize on the peptide backbone 
hydrogen–bonding network between the amino acids in i, i+4 and i, i+7 spacings for 1– and 2– 
helix turns, respectively. Unnatural amino acids are incorporated into these positions during the 
solid–phase peptide synthesis and are later chemically linked together to create a macrocyclic 
region that more easily adopts to α–helical structure. Stapled peptides are characterized through 
1) a direct binding assay such as SPR to determine the binding kinetics and affinity, 2) a 
 
Figure 22. Common α–stabilizing strategies.  
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biophysical assay such as circular dichroism (CD) to determine the helical content, and 3) a 
competition assay against target PPIs such as FP, TR–FRET, and ELISA to characterize their 
biochemical inhibition. Fluorescently tagged analogs of the stapled peptides are synthesized and 
used to characterize the cell permeability through fluorescence activated cell sorting (FACS) and 
confocal fluorescence microscopy.  
The most common stapling strategy is through ring–closing metathesis reaction termed 
hydrocarbon stapling developed by Blackwell and Grubbs32 using two O–allyl serines spaced i, 
i+4. Hydrocarbon stapling was optimized for α–helix structure stabilization under Schafmeister 
and Verdine33, in which α,α–disubstituted amino acids were used in place of O–allyl serines to 
increase helix propensity. In a ground-breaking study, Walensky et al. developed a series of BID 
BH3 hydrocarbon stapled peptides for binding proteins in the BCL–2 family34, and showed a 
drastic increase in cell permeability and in vivo stability and efficacy. The stapled BID BH3 
peptides had greater affinity than the native sequence to the target BCL–2, induced apoptosis in 
leukemia cells, and showed potency in leukemia xenografted mice35; since the literature still 
remains inconclusive on the improvements in cellular uptake from lactamisation or CuAAC36-37, 
the hydrocarbon stapling strategy gained traction as the peptide stapling strategy for therapeutic 
peptide developments. Since then, the hydrocarbon stapling strategy has been used to target p53–
MDM2/MDMX interaction38, HIV–139, small GTPase RAB25 40, PKA 41, eIF4E interactions1, 
NOTCH transcription factor complex42, and EZH2–EED complex43-44 among others. Inspired by 
these successes, alternative hydrophobic stapling strategies like perfluoroaryl–Cysteine SNAr45-46 
and hydrogen–bond surrogates47-50 emerge and continue to expand this exciting field.  
It should be noted that the hydrocarbon stapling strategy is still relatively new and in 
development. The hydrocarbon stapling strategy itself does not guarantee improved binding 
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affnity51 or cellular uptake52. Whether the disubstituted unnatural amino acids confer significant 
or any advantages to the helicity, proteolytic stability or binding affinity is under question53 and 
are currently under investigation. Although evidence suggests that increased cell permeability of 
stapled peptide may be through an energy–dependent endocytosis pathway54-55, the possibility or 
the exact method to exploit this pathway for stapled peptide delivery remains unknown and yet 
undiscovered.  
4.1.3 HYDROCARBON STAPLED PEPTIDES TARGETING EIF4E PROTEIN–
PROTEIN INTERACTIONS 
 
 The canonical binding motif of both 4E–BP1 and eIF4G adopt a short α–helix upon 
binding to eIF4E, and therefore make a great candidate for peptide stapling strategies. In 2012, 
 
Figure 23. Stapled peptides targeting eIF4E interactions. A) FP design1. FP probe sequence contained 
mutations that improved eIF4E binding affinity2. B) Kd as reported through SPR and FP, and helicity 
as reported through CD.  
Hotspot Y X X X X L Φ
4E-BP1 T R I I Y D R K F L M E C R N S
eIF4G E K K R Y D R E F L L G F Q F D
FP Probe K K R Y S R D F L L A L Q K
B
A
Peptide Sequence SPR/FP (Kd, nM) Helicity
Control KKRYSREFLLGF 100/195 0
sTIP-03 KKRYSRE*LL*F 3/4 45
sTIP-04 KKRYSR*QLL*L 5/11 63
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Zhou et al. conducted a phage display study to design potent eIF4E binding peptides2 and 
discovered that D5S and G11A mutation had increased the apparent binding affinity of the 
peptide to eIF4E by 4.6-fold and 2.3-fold, respectively (Figure 23A). 
Protein crystallization efforts and computational modeling studies showed that D5S 
mutation increased helicity of the peptide while G11A allowed for more compact packing of the 
bound peptide to the hydrophobic eIF4E surface. Implementations of two additional disruptive 
substitutions F8Q and F12L to the D5S G11A mutation sequence improved the apparent binding 
affinity further to 43 nM, greater than 10-fold increase from that of the linear eIF4G1 sequence 
(460 nM). With the excitement generated from the success of p53/MDM2 and BCL2–BH3 
hydrocarbon stapled peptide inhibitors, Lama et al had pursued rational design of stapled 
peptides targeting eIF4E interactions1 based on this potent linear eIF4G1 mutation sequence. Six 
hydrocarbon stapled peptides were synthesized and characterized, and two peptides – sTIP-03 
and sTIP-04 – had exhibited binding affinity over the native peptide by approximately 20–fold 
(Figure 23B). Molecular dynamics simulations and the overlaid predicted structures using the 
solved crystal structure of eIF4E found that these two potent peptides had different mechanisms 
of enhanced binding, adding another dimension of complexity to the rationale design of stapled 
peptides. Despite this promising in vitro data, the lead candidate sTIP-03 reduced eIF4E and its 
biomarker survivin only in absence of fetal calf serum (FCS)56-57, and further patents and studies 
developing sTIP-03 and sTIP-04 as therapeutic agents appear to have stopped.  
4.2 RESEARCH DESIGN 
As the development of sTIP-03 and sTIP-04 had shown, the hydrocarbon stapled (HCS) 
peptides provide an attractive alternative to small molecule modulators to target and disrupt the 
eIF4E interactions. Although sTIP–03 was bioactive only in absence of fetal calf serum (FCS)56-
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57, rigorous formulations can (and has) reduced serum binding properties of the HCS peptides 
and improved their cellular potency58. However, a more common practice is to optimize the 
sequence and the stapling strategy to limit the serum binding properties. Fortunately, eIF4G1 is 
not the only protein binding to eIF4E and 4E–BPs can provide an epitope to design and 
characterize HCS peptides on. Studies show that the ectopic expressions of 4E–BP1 in 
transformed cells lead to suppressed tumorigenicity in vitro59-60and in vivo61, and the aerosol 
delivery of 4E–BP1 gene inhibited the proliferation of lung cancer cells in K–rasLA1 model17. 
4E–BP1 peptide modified for cell permeability also induced apoptosis in lung cells17, and 4E–
BP1 peptide fused to gonadotropin–releasing hormone (GnRH) inhibited the growth of GnRH 
receptor–positive cells without significant cytotoxic effects to the host tissues17. Based on these 
mounting evidences, the 4E–BP epitope is a strong foundation to develop therapeutic HCS 
 
Figure 24. Overlay and amino acid sequences of the eIF4G mimetic sequence (blue, PDB: 5T46) and 
of the 4E–BP1 mimetic sequence (red, 4UED) bound to eIF4E (gray). Key side–chain residues of the 
canonical binding motif are displayed.  
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peptides on for targeting the CdT–driven cancers. As previously mentioned, 4E–BP1 is an 
intrinsically disordered protein62 that adopts a short –helical structure upon binding to eIF4E, 
thereby forming the 4E–BM of the PPI62 abiding to the sequence – YX4LΦ where Y,X,L, and Φ 
denote Tyr, any amino acid, Leu, and hydrophobic residue, respectively62-64 (Figure 24). Like 
sTIP–03 and sTIP–04, stabilization of the 4E–BP1 canonical binding helical motif would 
enhance eIF4E binding and yield greater inhibition from the reported benefits of peptide 
stapling65. Virtual sequential alanine mutagenesis (courtesy of Dr. Lauren Mishra) using the X–
ray crystal structure of 4E–BP1 peptide–eIF4E complex indicated that an i, i+4 staple at 
Lys57/Glu61 positions would leave minimal disturbance to the key interactions (Figure 25). 
Furthermore, a slight difference in residue contribution to the peptide binding affinity were 
predicted from high (Red, Minimized) and low (black, Rigid) ligand sampling 4E–BP1 peptide 
model. To further investigate this impact of high and low ligand sampling of the stapled peptides 
(and in effect, the difference between induced fit binding model and the conformational selection 
model), the Garner group focused on designing and synthesizing two distinct 4E–BP1 HCS 
peptides: a high ligand sampling peptide (induced fit) containing mono–substituted (S)–2–(4’–
 
Figure 25. Virtual sequential alanine mutagenesis on 4E-BP1. The docking poses of each 4E–BP1 
mutant peptide with eIF4E were analyzed against that of the native 4E–BP1 with eIF4E using Glide, 
with (Minimized) and without (Rigid) energy minimization prior to Glide scoring. A higher Glide 
Score indicates an unfavorable mutation, and therefore, a greater contribution to the ligand binding 
affinity.  
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pentenyl)glycines at the stapling sites (mHCS)65, and a low ligand sampling (conformational 
selection) peptide containing more commonly used (S)–2–(4’–pentenyl)alanines (HCS) (Figure 
26). mHCS 4E–BP1 would be subjected to additional structural reorganization upon binding 
than HCS 4E–BP1 from the lack of methyl moiety on the 
unnatural amino acid alpha carbon, and potentially mimic the greater plasticity of disordered 
protein like 4E–BP1. The resulting impact in binding kinetics and inhibitory potency of mHCS 
4E–BP1, HCS 4E–BP1, and various analogs were evaluated. 
4.3 HCS STAPLED PEPTIDES 
4.3.1 4E–BP1 LINEAR SEQUENCE OPTIMIZATIONS 
Despite the strong inhibitory potency of the 4E–BP1 peptide (as evaluated by PPI cat–
ELCCA), methionine oxidation and cysteine-induced peptide dimerization posed difficulties in 
4E–BP1 peptide synthesis, purification, handling and storage. Prolonged storage of the peptide 
stocks often resulted in the loss of in vitro activity and precipitation upon thawing, all with the 
accompanying dimerization and/or a gain of +16 or +32 confirmed by LC–MS. Additionally, the 
4E–BP1 peptide displayed poor aqueous solubility and was prone to aggregation which led to a 
significant product loss. 4E–BP1 sequence optimizations were required to identify and evaluate 
 
Figure 26. Hydrocarbon stapled peptides. mHCS and HCS peptides are synthesized with 
monosubstituted pentenylglycine and disubstituted pentenylalanine, respectively. 
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the methionine and cysteine bio–isosteres and substitutions (Figure 27). 4E–BP1 and peptides 
1–5 were synthesized and characterized. Peptide 1 was derived from 4E–BP2 protein, a 
homologous protein in the 4E–BP family that is less characterized than 4E–BP1 and more highly 
expressed in the brain65. As expected, peptide 1 (19 ± 1 nM) reported similar low nanomolar 
inhibitory potency as 4E–BP1 peptide (31 ± 1 nM) without the concerns of methionine oxidation
 
and peptide dimerization. Although M60L and E61D substitutions from 4E–BP1 to 4E–BP2 
sequence carry relatively minor molecular differences, it was encouraging that the C62R was 
well-tolerated since many cell penetrating peptides are identified by net positively charged 
 
 
Figure 27. Linear sequence characterization. 4E–BP1 peptide mimetic sequence optimizations and 
inhibitory potencies. PPI cat–ELCCA dose response curves corresponding of linear peptides 4E–BP1 
(black), 1 (red), 4 (blue), and 5 (green). All experiments were conducted in triplicates (n=3) and 
shown as the mean ± SD. 
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peptides66. Unfortunately, synthesis and purifications of mHCS–2 proved difficult and required 
alternative sequence optimizations. Peptide 2 incorporated a reported bio-isostere of methionine, 
norleucine67, and the C62R substitution that was well tolerated in peptide 1. Similarly, peptide 3 
incorporated norleucine in place of methionine and C62K substitution based on the sequence of 
homologous protein 4E-BP3. Prior to the final purifications of peptides 2 and 3, the Garner 
group discovered that the full–length 4E–BP1 protein carrying M60A mutation had significant 
loss in inhibitory potency compared to the WT 4E–BP1 (Figure 15A, Chapter 2) and confirmed 
a similar loss of inhibitory potency with peptide 4. Peptide 4 suffered greater than 10–fold 
increase in the apparent IC50 (164 ± 1 nM) in comparison to the 4E–BP1 peptide and peptide 1. 
Peptides 2 and 3 experiments were abandoned, and no further attempts were made to substitute 
the native M60 and C62 residues. Instead, to reduce the nonpolar nature of the peptide and to 
increase its solubility, G49, T50, and N64 of 4E–BP1 peptide were eliminated to produce 
peptide 5. Peptide 5 benefited from easier synthesis, purification, and higher aqueous dissolution 
(> 1.0 mM) than the other linear peptides discussed; surprisingly, peptide 5 also yielded the 
highest inhibitory potency of 7 ± 1 nM and became a strong candidate for HCS peptide 
development. Overall, the modifications to the 4E–BP1 peptide sequence reduced its inhibitory 
potency, and the identification of bio–isosteres to the native M60 and C62 residues was 
unsuccessful. In addition to 4E–BP1 peptide, peptide 5 was identified as good candidates for 
further HCS developments.  
4.3.2 RING CLOSING METATHESIS 
The stapling procedure was adapted68 using Grubbs catalyst generation I and II (Figure 
28A). It should be noted that the N-terminal Fmoc can be removed upon prolonged exposure to 
RCM reaction conditions, and potentially nullify further RCM reaction from the increased 
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competition of the free amine to the olefinic substrate binding site on the catalysts. The catalysts 
are light and moisture sensitive and suffer from a loss of RCM efficiency over time. Investigators 
use the Grubbs Catalyst generation I34, 42, 52, 69-70 and II71-74 interchangeably depending on the 
 
 
Figure 28. Ring closing metathesis. A) Grubbs Generation I and II catalysts for RCMs. B) RCM 
mechanism categorized into 3 steps: Catalyst loading, Reaction, and Catalyst Regeneration. The 
ligand ortho– to the ruthenium complex are tricyclohexylphosphine and N–heterocyclic carbenes for 
generation I and II, respectively.  
A
B
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required reactivity and the reaction conditions. The reaction mechanism for both generation I and 
II catalysts are identical (Figure 28B), in which the phosphine group dissociates to yield a 
reactive 14–electron ruthenium complex that binds to the olefinic substrate. The kinetic 
superiority of generation II catalyst comes from the greater selectivity for binding to the olefinic 
substrates in the presence of this dissociated tricyclohexylphosphine group75. The first olefinic 
substrate is loaded onto the catalyst, replacing the styrene group. And then, the second olefinic 
substrate forms a metallo–organic complex with the catalyst loaded with the first olefinic 
substrate, and the alkene bond cyclizes the two terminal olefins together. The catalyst is 
regenerated by releasing ethane as a by–product. The reaction mechanism clearly suggests the 
possibilities of forming a regioisomer mixture in the RCM depending on the olefinic substrate 
orientation (Figure 28B, cis– and trans– mechanism). In fact, Schaffmeister et al.33 originally 
reported two separable HCS peptides with identical molecular mass for i, i+7 stapled RNAse A 
peptide with distinct CD profiles (18% to 7%), indicating a significant difference in the alpha 
helix structure. Another study73 reported different ratios of the double bond diastereomeric 
products upon using Grubbs Generation I catalyst and Generation II/Hoveyda–Grubbs catalyst.  
Douse et al.70 confirmed the presence of E– and Z– isomers of different activities targeting 
Plasmodium falciparum myosin A (myoA)−myoA tail interacting protein. Verdine et al. also 
note that the RCM reactions will yield one major olefin isomer along with a minor isomer68. The 
isomer ratio appears to be largely determined by the R1 group orthogonal to the olefinic 
substrate plane (Figure 28B), and to the flexibility and the length of the olefinic substrate76. 
Unsurprisingly, the high plasticity and flexibility of mHCS peptides led to regioisomeric 
mixtures that was unobserved in the HCS peptides. For the presented experiments, mHCS 
peptides were isolated and used as a regioisomeric mixture, and the resulting IC50 was reported 
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from this mixture. The further investigations into the isomers’ isolation and characterizations are 
detailed in a later section (Chapter 4.4) 
4.3.3 MHCS PEPTIDES 
Encouraged by the potent inhibition displayed by the 4E–BP1 peptide, peptide 1 and 
peptide 5, mHCS analogs of these peptide candidates were made (Figure 29A). RCM reactions 
were carried out using Grubbs Catalyst Generation I following the established protocol68. 
Unfortunately, mHCS–1 could not be further characterized due to the insufficient purity. All the 
 
Figure 29. mHCS-4E-BP1. A) mHCS peptides of 4E–BP1, 1 – 3, and 5 and their in vitro inhibitory 
potency. mHCS–1 was not assayed due to the lack of purity. mHCS 4E–BP1 (black), mHCS–2 (red), 
mHCS–3 (blue), and mHCS–5 (green). B) analytical HPLC spectra of stock mHCS 4E–BP1 purity 
confirmed by LC–MS. The dose-responsive curves were conducted in triplicates (n=3) and shown as 
the mean ± SD. 
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mHCS peptides carried a minimum of two closely eluting peaks (Figure 29B, rest LC spectra in 
appendix) with identical molecular mass. The close retention time and the molecular mass 
suggested that the co–eluting peaks were isomers of the desired mHCS peptides. Despite the 
known synthesis and isolations of regioisomeric HCS peptides, the finding of isomers in i, i+4 
positioned stapled peptides were surprising. While the mHCS peptides were designed 
specifically to contain the greater ligand sampling to target eIF4E (by having a more flexible 
hydrocarbon staple lacking the Cα methyl group), the reported regioisomers were only observed 
using the highly flexible unnatural amino acids positioned at i, i+7 positions with long 
hydrocarbon linkers (8–9 methylene groups). The co–eluting peaks were inseparable despite the 
attempted HPLC purification method developments, re–synthesis and iterative purifications. For 
the initial PPI cat–ELCCA evaluations, the mHCS peptides were isolated, purified, and used 
after confirming purity through the LC–MS total ion count (TIC) spectra. 
The failure to purify and isolate mHCS–1 despite the repeated synthetic and purification 
attempts were discouraging given the inhibitory potency of peptide 1. mHCS 4E–BP1 was 
plagued by decreased aqueous solubility and difficult purifications, all without an improvement 
in its inhibitory potency (IC50 = 31 ± 2 nM) compared to the 4E–BP1 peptide. mHCS–5 had 
high aqueous solubility comparable to that of peptide 5 but suffered from a 17–fold loss in IC50 
(122 ± 1 nM); this poor translation of inhibitory potency from the linear peptides to the mHCS 
peptides led to the renewed attempts to evaluate mHCS–2 and mHCS–3. Unfortunately, both 
mHCS–2 and mHCS–3 exhibited poor inhibitory potency in comparison to that of mHCS 4E–
BP1 with IC50 of 387 ± 1 nM and 152 ± 2 nM, respectively. Although the mHCS peptides failed 
to elicit a significant improvement over their linear peptides in in vitro assays like PPI cat–
ELCCA, the mHCS peptides could still have greater inhibitory effect in cell treatments due to 
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changes in cell permeability and peptide stability. mHCS 4E–BP1 retained the inhibitory 
potency of 4E–BP1 peptide and was selected for further cellular treatment studies.  
4.3.4 HCS PEPTIDES 
Encouraged by the potent inhibition of 4E–BP1 peptide and mHCS 4E–BP1, HCS 4E–
BP1 was synthesized and characterized (Figure 30A). HCS–5 was not synthesized due to the 
observed loss in inhibitory potency of mHCS–5. sTIP–04, a reported eIF4G1 mimetic stapled 
 
Figure 30. HCS peptides. A) HCS peptides of 4E–BP1, and sTIP–04 and the in vitro inhibitory 
potency. HCS 4E–BP1 (black), sTIP–04 (red). B) analytical HPLC spectra of stock HCS 4E–BP1 
purity confirmed by LC–MS. The dose-responsive curves were conducted in triplicates (n=3) and 
shown as the mean ± SD. 
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peptide77, was also synthesized and characterized as a HCS peptide control. RCM reactions were 
carried out using Grubbs Catalyst Generation I following the established protocol68. Contrary to 
the purifications of mHCS 4E–BP1, both sTIP–04 and HCS 4E–BP1 purifications were more 
facile, without significant HPLC purification method development and iterative purifications. 
Furthermore, both sTIP–04 and HCS 4E–BP1 eluted as one clearly defined peak (Figure 30B, 
the rest are available in appendix) and suggested the presence of just one isomer. HCS 4E–BP1 
was purposely designed to exhibit lesser ligand sampling to target eIF4E (by having a more rigid 
hydrocarbon staple due to the Cα methyl group); the increased rigidity likely limited ligand 
sampling during the RCM reaction as well, leading to the formation of the more favored Z– 
isomer. Unnatural amino acid (S)–2–(4’–pentenyl)alanine is the most commonly used to generate 
the HCS peptides; based on this evidence and on the lack of reports concerning the regioisomer 
formations of i, i+4 positioned HCS peptides using (S)–2–(4’–pentenyl)alanine, regioisomeric 
mixtures may not be a notable problem in general HCS peptide studies.  
In comparison to mHCS 4E–BP1, HCS 4E–BP1 exhibited greater aqueous solubility 
(comparable to that of 4E–BP1 peptide). More importantly, HCS 4E–BP1 exhibited greater than 
7–fold increase in the inhibitory potency (IC50 = 4 ± 1 nM) compared to the 4E–BP1 peptide. 
Although more studies are required to validate the nature of high and low ligand sampling in 
regard to disordered protein like 4E–BP1, the different inhibitory potencies of mHCS 4E–BP1 
and HCS 4E–BP1 suggests that a low–ligand sampling, rigid α–helix mimetic resembling the 
bound 4E–BP1–eIF4E complex could be a better inhibitor. Extrapolating on this hypothesis, the 
difference between mHCS 4E–BP1 and HCS 4E–BP1 could suggest that 4E–BP1–eIF4E 
interaction may be driven by a “lock–and–key” like rather than an “induced–fit” like mechanism, 
and that the high plasticity of disordered proteins like 4E–BP1 may not be critical to mimic for 
 98 
designing inhibitors and stapled peptides. Unsurprisingly, sTIP–04 was also a potent inhibitor of 
4E–BP1 – eIF4E interaction (IC50 = 23 ± 2 nM) without the easily oxidized methionine and 
cysteines. However, sTIP–04 is effective only as an in vitro control model due to its serum–
binding properties and its limited use in cellular treatments.  
4.3.5 CELLULAR TREATMENTS 
 
The cellular efficacies and cellular penetrance of 4E–BP1 peptide, mHCS 4E–BP1, and 
HCS 4E–BP1 were evaluated in MDA–MB–231 cells. MDA–MB–231 is a triple negative breast 
cancer cell line exhibiting overexpression of eIF4E and eIF4G in addition to 4E–BP1 
hyperphosphorylation78, and is a useful model cell line to evaluate the inhibition of eIF4E 
interactions. The cellular permeability of 4E–BP1, mHCS 4E–BP1, and HCS 4E–BP1 were 
evaluated through fluorescence assorted cytometry sorting (FACS)78. The fluorescein-conjugated  
peptides were synthesized and purified; the N–terminal β–alanine residues prior to fluorescein 
provided a non–degradable linker to prevent TFA–induced degradation of the peptide78. The 
resulting fluorescein tagged 4E–BP1, mHCS 4E–BP1, and HCS 4E–BP1 (labeled f4E–BP1, 
fmHCS 4E–BP1, fHCS 4E–BP1, respectively) were difficult to solubilize in aqueous media, 
easily prone to precipitation, and required dissolution in a solution of 1:2 DMF:H2O v/v which 
limited the FACS assay concentration to 1.0 µM. f4E–BP1 peptide precipitated within minutes 
of contacting the cellular media, and therefore could not be analyzed through FACS (data not 
shown). fHCS 4E–BP1 was found to readily enter MDA–MB–231 cells and exhibited a higher 
fluorescence intensity than the fluoresceine control cells consistently over the replicates and re–
synthesis (Figure 31A). Unfortunately, fmHCS 4E–BP1 showed highly variable cell 
permeability between the biological replicate experiments and the re–synthesis, and its cell 
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penetrance was determined to be inconclusive. The inconsistencies of fmHCS 4E–BP1 FACS 
results may arise from the previously noted presence of regioisomers, and (or) sample dissolution 
and formulation. Despite the inconclusive cell penetrance of fmHCS 4E–BP1, cellular efficacy 
treatments showed similar inhibitory potencies between mHCS 4E–BP1 and HCS 4E–BP1 in 
m7GDP cap pull–down assay28 (Figure 31B). The addition of hydrophobic fluoresceine and 2x 
β–alanines may have decreased solubility, induced aggregations, and altered net structure of 
mHCS 4E–BP1; alternatively, ChloroAlkane Penetration Assay developed by Kritzer and co–
 
Figure 31. Cellular assays for mHCS and HCS peptides. A) Cellular permeability of FITC–labeled 
HCS–4E–BP1 as determined via flow cytometry (n = 3) in MDA–MB–231 cells. Cells were treated at 
1 µM for 6 h. Ctrl: 1:2 DMF:H2O v/v, Fl: dichlorofluoresceine. B) Cellular inhibitory activities of the 
linear 4E–BP1 and HCS–4E–BP1 peptides as determined via m7GDP cap affinity chromatography. 
Inhibition of the eIF4E−4E–BP1 and eIF4E−eIF4G PPIs in C) MDA–MB–231 cells, and (C) HCT116 
cells (2.5 M), and H1299 cells (2.5 M). In all cases, cells were treated for 6 h and eIF4E was used 
as a normalization control.  
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workers28 could measure the cellular penetrance of mHCS 4E–BP1 by implementing a relatively 
minor chemical change to the peptide (a terminal chloro–alkane).  
To test the inhibitory effect on eIF4E PPIs, cells were treated with varying concentrations 
of peptides and the resulting lysates were analyzed using a m7GDP cap pull–down assay. 4E–
BP1 peptide showed a modest inhibition at the highest concentration tested (5 µM) likely due to 
its poor cellular uptake79 (Figure 31C). Both mHCS 4E–BP1 and HCS 4E–BP1 exhibited 
greater inhibition of eIF4E interactions than 4E–BP1 peptide under the identical dosage, but 
similar efficacies as estimated by the band intensities of eIF4E bound eIF4G1 and 4E–BP1 
(Figure 31C). Cellular inhibitory effects were analyzed on two additional cell lines that also 
exhibit hyperactivated CdT: HCT116 colorectal carcinoma cells79 and H1299 non–small cell 
lung cancer cells (Figure 31D)79. Similar to the results observed in MDA–MB–231 cells, HCS 
4E–BP1 showed promising activity in both cell lines, demonstrating its potential as a chemical 
probe for interrogating the eIF4E PPIs. This is particularly important, as the existing small 
molecule inhibitors of the eIF4E−eIF4G PPI, 4EGI–179 and 4E1RCat,79 contain structural 
features that classify them as pan–assay interference compounds or PAINS79-80. mHCS 4E–BP1 
exhibited a limited potency in inhibiting the eIF4E interactions in colorectal carcinoma disease 
model. In lieu of the overall lower inhibitory efficacies, the difficult peptide preparations, and the 
inconsistent cellular permeability, mHCS 4E–BP1 was concluded as an unreliable chemical 
probe for interrogating eIF4E PPIs. HCS 4E–BP1 presents the first documented cell permeable 
HCS peptide targeting eIF4E PPIs that remain bio–active in presence of serum, and thus hold 
potential as a valuable probe targeting the CdT initiation. 
 101 
4.4 HYDROCARBON STAPLED PEPTIDES: REGIOISOMERS 
4.4.1 MHCS CASE STUDY 
As previously mentioned, all the mHCS peptides contained co–eluting peaks of identical 
molecular mass, and were hypothesized to be the regioisomers of i, i+4 positioned hydrocarbon 
stapled peptides. Extensive semi–prep HPLC purification optimizations and repeated attempts to 
 
 
Figure 32. mHCS-4E-BP1 diastereomers. A) the semi–prep HPLC purification (left) and the 
analytical spectra (right) of mHCS–i (blue) and mHCS–ii (red) B) in vitro characterizations of 
mHCS–i and mHCS–ii by PPI cat–ELCCA (n=3) C) Cellular inhibitory activities of the 4E–BP1 
peptide, mHCS–i, mHCS–ii, and HCS 4E–BP1 as determined via m7GDP cap affinity 
chromatography in MDA–MB–231 cells. In all cases, cells were treated for 6 h and eIF4E was used as 
a normalization control. 
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force synthesis of one isomer over the other remained mostly unsuccessful. However, one such 
attempt led to two separated mHCS 4E–BP1 regioisomers containing one early eluting isomer 
mHCS–i and later eluting mHCS–ii  (Figure 32A). mHCS–i exhibited greater than 3–fold 
reduction in the IC50 in comparison to mHCS–ii despite the lack of difference in the intrinsic α–
helicity as measured by CD (Figure 32B). Most surprisingly, mHCS–i exhibited a greater 
potency in cellular treatment than mHCS–ii, 4E–BP1 peptide, and HCS 4E–BP1, and had 
reduced eIF4E associated eIF4G1 and 4E–BP1 levels to completion at 5 µM (Figure 32C). 
Encouraged by this result, further biophysical characterizations of mHCS regioisomers were 
 
Figure 33. Peptide diastereomer NMR. A) Overlaid 1D NMR spectra of mHCS–i (black) and 
mHCS–ii (red). B) 1D NMR spectra of HCS 4E–BP1 (blue). Significant water contamination and the 
poor solubility yielded in unresolved low signal olefinic peaks in all cases 
~50 Hz
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B
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pursued through NMR.  
The literature shows that the chemical shifts and the coupling constants representative of 
the E– and Z– isomers70, 76, 81-83 are identified by 1D and/or a HOMO–decoupling NMR  
experiments selective for the adjacent methylene protons.  mHCS–i and mHCS–ii NMR 
experiments were limited by the poor peptide solubility in water, DMSO, and other organic 
solvents which yielded low signal, unresolved peaks. And despite the extensive lyophilization 
and drying, water (δ 4.6) could not be removed thoroughly from the peptide sample and drowned 
the already low olefinic proton peak between δ 5.4 to δ 5.0. mHCS–i and mHCS–ii spectra 
could be overlaid almost perfectly on top of one another, with special exception at the olefinic 
proton region (Figure 33A). Measuring the crude coupling constants between the two dominant 
 
Figure 34. mHCS-5i and mHCS-5ii NMR. A) the analytical spectra of mHCS–5i (blue) and mHCS–
5ii (red) B) in vitro characterizations of mHCS–5i and mHCS–5ii by PPI cat–ELCCA, and SPR 
(n=3). 1D NMR spectra and analysis of mHCS–5i (C) and mHCS–5ii (D) with alkene 3JHH values of 
20 Hz and 8 Hz, respectively.  
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peaks82-83 of mHCS–ii yielded 26 Hz that failed to fit neither E– nor Z– isomer and required a 
complex second–order splitting analysis for characterization. HCS 4E–BP1 also lacked the 
exceptional aqueous, DMSO, and other solvent solubility to acquire a well resolved olefinic 
proton region and suffered from a similar water peak interference (Figure 33B). As expected, 
measuring the crude coupling constants between the two dominant peaks82-83 of HCS 4E–BP1 
yielded approx. 50 Hz that failed to fit neither E– nor Z– isomer, and again suggested that a more 
complex second–order splitting analysis was required for characterization.   
Although mHCS–5 lacked the in vitro inhibitory potency and the direct binding affinity, 
it yielded two isolatable isomers mHCS–5i (blue) and mHCS–5ii (red) in high purity that 
mHCS 4E–BP1 had never achieved (Figure 34A). mHCS–5i and mHCS–5ii inhibitory 
potencies and direct binding affinities to eIF4E did not produce the stark difference that mHCS–i 
and mHCS–ii had exhibited (Figure 34B); however, the two isomers dissolved extremely well 
in deuterated acetic acid for NMR studies. The analysis of these well–resolved, complex second–
order coupling multiplex representative of the olefinic protons indicated that mHCS–5i and 
mHCS–5ii were E– and Z– isomers with 3JHH values of 20 Hz and 8 Hz, respectively (Figure 
34C, D). The mHCS–5 regioisomer case revealed that the two peptide isomers can be identified 
through 1D NMR with the high resolution, but these isomers may not necessary elicit different 
bioactivities. Thus, when the explicit differences are present between the peptide isomers’ 
activities like for mHCS–i and mHCS–ii, a confirmation or an elimination of the isomers’ 
impact in the difference is critical for further medicinal chemistry campaigns.  
 In attempts to establish a detailed systematic workflow to identify HCS peptide isomers, 
sTIP–04 was used as a model peptide due to its extremely high aqueous solubility (> 5.0 mM) 
and the unreactive amino acid side chains. Since sTIP–04 only had one peak in the analytical LC 
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spectrum, and in general, RCM reactions of i, i+4 positioned olefinic acids favor Z– isomer84, 
sTIP–04 was hypothesized to be a Z– isomer. In order to simplify the complex second–order 
coupling of the olefin protons, homo-decoupling of the methylene protons during 1D NMR 
acquisition was attempted. First, double–quantum filtered COSY (dqfCOSY) experiment was 
performed on sTIP–04 to identify the chemical shift regions in which the methylene protons 
coupling to the olefinic protons resided which was confirmed between δ 2.0 – 1.8 (Figure 35A). 
And then, a 1D homo-decoupling selective for the methylene protons at a chemical shift region 
of δ 2.0 – 1.8 (Figure 35B) showed a coupling value of 11 Hz between the two olefinic protons 
and confirmed that sTIP–04 is indeed a Z– isomer. Unfortunately, neither mHCS 4E–BP1 nor 
 
Figure 35. sTIP-04 NMR. A) dqfCOSY 2D NMR of sTIP–04. The cross–peaks representative of the 
olefinic protons (δ5.4 – 5.2) and of the coupling methylene protons (δ1.95 – 1.8) were identified. B) 
Stacked sTIP–04 1D NMR (red) and homo‐decoupling of the protons at a chemical shift of 2.0 – 1.8 
ppm (blue) during the acquisition. The resulting coupling constant of 11 Hz suggest that sTIP–04 is a 
Z– isomer.  
J = 11 Hz
A
B
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HCS 4E–BP1 could be dissolved in sufficient concentration to achieve the high signal required 
for dqfCOSY and the representative crosspeaks of the methylene protons were drowned in the 
experimental noise. Since HCS 4E–BP1 used identical olefinic unnatural amino acid as sTIP–04 
and was validated to contain just one peptide peak by HPLC, HCS 4E–BP1 was hypothesized to 
be a Z– isomer and further experiments were not pursued to confirm the isomer. mHCS 4E–BP1 
was re–synthesized and the two diastereomeric peptides were isolated as a slight mixture for 
more extensive NMR studies. The peptides were designated mHCS–i and mHCS–ii based on 
the earlier and later elution retention time, respectively. Since dqfCOSY experiments required 
higher solubility than neither mHCS–i nor mHCS–ii could achieve, TOCSY was used to 
determine the approximate chemical shift region that the olefin coupling methylene protons 
resided in. mHCS–ii TOCSY indicated that the vinyl protons residing in the chemical shift 
region between δ 5.4 and δ 5.2 were coupling to the methylene protons Ha and Hb in δ 2.1 – δ 
1.6, and δ 1.4 and δ 1.1, respectively (Figure 36A). However, the 1D homo-decoupling selective 
for the methylene protons at the chemical shift region of δ 2.1 – 1.6 failed to simplify the 
second–order coupling of the olefinic protons between δ 5.4 and δ 5.2 and the molecular 
structural determinations of mHCS–i and mHCS–ii were inconclusive (Figure 36B). Further 
attempts to identify and characterize mHCS–i and mHCS–ii were halted due to the difficulties 
in the sample preparation from the rapid methionine oxidation and peptide dimerization in the 
NMR acquisition condition (RT, ~36 h).  
  As a final attempt to simplify the mHCS–i and mHCS–ii synthesis and purification for 
cellular treatment studies, RCM reaction was performed using Grubbs Generation I and 
Generation II catalysts to synthesize mHCS–G1 and mHCS–G2, respectively. Similar to the 
different ratios of the diastereomeric products upon using Grubbs Generation I catalyst and 
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Generation II/Hoveyda–Grubbs catalyst73, the kinetic advantage of Generation II catalyst over 
the Generation I catalyst could shift the reaction equilibrium towards one isomer over the other 
and reproduce the previously observed in vitro properties of mHCS–i and mHCS–ii. 
Surprisingly, mHCS–G1 was a mixture containing approx. equal amounts of the two co–eluting 
peaks while mHCS–G2 yielded a mixture favoring the isomer with the later retention time 
 
Figure 36. mHCS-ii NMR. A) TOCSY 2D NMR of mHCS–ii. The cross–peaks representative of the 
vinyl proton (δ 5.4 – δ 5.2) coupling methylene protons Ha (δ 2.1 – δ 1.6) and Hb (δ 1.4 –δ 1.1) were 
identified. B) Stacked mHCS–ii1D NMR (red) and homo‐decoupling of the protons at a chemical 
shift of 2.1– 1.6 ppm (blue) during the acquisition 
23 Hz
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(Figure 37A). Contradictory to the previous results of mHCS–i and mHCS–ii, mHCS–G2 that 
contained the late eluting peptide as the dominant isomer (similar to mHCS–ii) exhibited 
enhanced inhibitory potency (IC50 14 ± 3 nM) and direct binding to eIF4E (Kd 19.1 ± 0.1 nM) 
over that of mHCS–G1 (IC50 and Kd of 31 ± 5 nM and 28.2 ± 0.1 nM, respectively) (Figure 
37B). Ultimately, the campaign to isolate and characterize the possible two isomers of mHCS 
4E–BP1 was terminated when mHCS–G1 and mHCS–G2 failed to reproduce the drastic 
difference in inhibiting the eIF4E interactions in cellular treatments (Figure 37C). The reported 
mHCS 4E–BP1 studies (PPI cat–ELCCA, SPR, CD, cellular treatments, FACS) were completed 
using the regioisomeric mixtures unless otherwise noted.  
 
 
 
Figure 37. Investigation of Grubbs’ catalysts. A) the analytical spectra of mHCS–G1 (red) and 
mHCS–G2 (blue), B) in vitro characterizations of mHCS–G1 and mHCS–G2 by PPI cat–ELCCA, 
SPR, and CD (n=3), C) Cellular inhibitory activities of mHCS–G1 and mHCS–G2 as determined via 
m7GDP cap affinity chromatography. Inhibition of the eIF4E−4E–BP1 and eIF4E−eIF4G PPIs in 
MDA–MB–231 cells. In all cases, cells were treated for 6 h and eIF4E was used as a normalization 
control. 
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4.4.3 SURFACE PLASMON RESONANCE AND CIRCULAR DICHROISM 
A subset of notable peptides and isomers were selected for further biophysical 
characterizations through SPR and CD (Table 3, courtesy of Erin Gallagher). A detailed 
characterization of the peptide binding kinetics and their inherent α–helix structure could 
corroborate the critical differences between peptides representing induced fit binding model 
(mHCS 4E–BP1) and of conformational selection model (HCS 4E–BP1) in the disordered 
protein – ordered protein interactions. There is an on–going discussion on whether the interaction 
between an intrinsically disordered protein like 4E–BP1 and an ordered protein like eIF4E is 
mainly dictated by the increases in ka
85
 similar to those observed between ordered proteins or by 
the decreases in kd
85. Interestingly, HCS 4E–BP1 displayed both an increase in ka and a decrease 
in kd from 4E–BP1 peptide suggesting a binding mechanism through a combination of 
conformational selection and an induced fit with fast folding upon binding. On the other hand, 
mHCS 4E–BP1 suffered from a 2.3–fold reduction in ka and a similar increase in kd to maintain 
a comparative binding affinity to 4E–BP1 peptide, indicating that the greater ligand sampling 
had hindered the initial association of the disordered peptide to its target but allowed for a 
 
Table 3. Peptides selected for further biophysical characterizations. Protocols for SPR and CD are 
detailed in appendix. mHCS–5i and mHCS–5ii were re–synthesized for SPR and CD experiments and 
were assigned label by the order of elution by LC. All the experiments were conducted in triplicates 
(n=3) and shown as the mean ± SD. 
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stronger retention of the interaction. HCS 4E–BP1 also had significant helical structure (approx. 
4–fold) than mHCS 4E–BP1 and confirmed that the conformational selection model had indeed 
benefited from increased helical structure. In general, the changes in peptide helicity correlated 
positively with the changes in binding affinity and inhibitory potency as observed from peptide 5 
and mHCS–5i and mHCS–5ii, and 4E–BP1 peptide and HCS 4E–BP1. 
Although the molecular analysis of mHCS–G1 and mHCS–G2 isomers were 
unsuccessful, both SPR and CD results indicate that the peptides were indeed different. mHCS–
G2 had comparable increase in kd as HCS 4E–BP1 and greater helicity than mHCS 4E–BP1 
and suggest that it may have similar molecular structure to HCS 4E–BP1. Despite the strong 
case that mHCS 4E–BP1 and mHCS–G2 are regioisomers, the difference in their bioactivities 
are minute and inconsistent. Similar analogs mHCS–5i and mHCS–5ii failed to exhibit 
differences in their bioactivities. Thus, although the regio-isomerizations of the mHCS peptides 
could indeed be a real phenomenon in mHCS–G1 and mHCS–G2, and mHCS–5i and mHCS–
5ii, the total isolation and characterizations of the two isomers may be unnecessary and labor 
intensive with little net benefits in the probe development. 
4.5 CONCLUSION 
The presented investigation into the impact of high and low ligand sampling – and in 
effect, the difference between induced fit binding model and the conformational selection model 
– using mHCS 4E–BP1 and HCS 4E–BP1, respectively, indicate that the disordered 4E–BP1 – 
eIF4E interaction may largely follow the low ligand sampling conformational selection model. 
The greater structural plasticity of mHCS 4E–BP1 resulted in comparable α–helicity structural 
composition, direct binding affinity, and inhibitory potency to 4E–BP1 peptide. Conversely, 
HCS 4E–BP1 resulted in greater α–helicity structural composition, direct binding affinity, and 
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inhibitory potency than both mHCS 4E–BP1 and 4E–BP1 peptide. The intrinsically disordered 
protein (IDP) dependent interactions like that of 4E–BP1 – eIF4E are widespread in biology and 
are involved in many important biological processes, and this investigation suggests that 
mimicking the plasticity of the interaction may be unnecessary in their biotherapeutics design. 
The greater flexibility of the hydrocarbon linkers on mHCS peptides complicated the 
robust RCM reaction by producing a regioisomeric peptide mixtures. Their mere presence 
necessitates the (often) difficult HPLC purifications and molecular characterizations. And while 
the bioactivities of the regioisomeric peptides may be similar as in the cases of mHCS–5i and 
mHCS–5ii, or different as in the case of mHCS–i and mHCS–ii, the inconsistent generation of 
isomer mixture should caution further stapled peptide designs using (S)–2–(4’–pentenyl)glycine. 
Based on the findings of HCS peptides targeting the eIF4E interactions, the Garner group 
remains focused on identification and applications of other stapling strategies using lactam and 
disulfide formations to improve the cellular activity and permeability of 4E–BP1 peptides.  
4.6 EXPERIMENTAL 
4.6.1 GENERAL MATERIALS AND METHODS 
General chemistry methods. RP–HPLC was performed using binary gradients of solvents A and 
B, where A is 0.1% HCO2H in water and B is 0.1% HCO2H in acetonitrile or 0.1% HCO2H in 
methanol. Analytical RP–HPLC was performed using an Agilent 1260 Infinity HPLC equipped 
with a ZORBAX Eclipse SB–C18 column (4.6 × 150 mm; 5 μm) at a flow rate of 1 mL/min, 
with detection at 214 and 254 nm. Preparative RP–HPLC was performed using an Agilent 1260 
Infinity HPLC equipped with a PrepHT SB–C18 column (21.2 × 150 mm; 5 μm) at a flow rate of 
12.6 mL/min, with detection at 214 and 254 nm. In all cases, fractions were analyzed off–line 
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using Agilent Q–TOF HPLC–MS. Peptide stock concentrations were determined using amino 
acid analysis. 
 
General assay and biology methods. SPR was performed using a SensiQ Pioneer instrument and 
a HisCap chip (three–dimensional hydrogel surface) with 3 channels in series. BL21DE3 E. coli 
were used for protein expression. CD spectra were recorded on a Jasco I–1500 CD–
Spectropolarimeter. IC50 values were determined using PPI cat–ELCCA as reported85. 
Chemiluminescence data was collected on a BioTek Cytation3. Gels were imaged on a 
ProteinSimple Fluorchem M Gel Imager. MDA–MB–231 and H1299 cells were a kind gift from 
Dr. Nouri Neamati. HCT116 cells were a kind gift from Dr. Judy Sebolt–Leopold. MDA–MB–
231 cells were grown in RPMI–1640 media supplemented with 10% FBS (Atlanta Biologicals), 
2 mM glutamine and 1% penicillin–streptomycin. H1299 cells were grown in RPMI–1640 media 
supplemented with 10% FBS and 2 mM glutamine. HCT116 cells were grown in McCoy’s 5A 
media supplemented with 10% FBS and 2 mM glutamine. All cell lines were authenticated by 
STR profiling. 
 
Data analysis. All data was analyzed using GraphPad Prism version 6.01 for Windows 10 
(GraphPad Software, www.graphpad.com).  
 
Materials. Fmoc–protected amino acids and Rink amide MBHA resin were purchased from P3 
Biosystems and used as received. Fmoc–(S)–2–(4–pentenyl)glycine–OH and Fmoc–(S)–2–(4–
pentenyl)alanine–OH were purchased from ArkPharm and used as received. Horseradish 
peroxidase (HRP), streptavidin–coated 384–well plates (white, high binding capacity; cat 
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#15505), and SuperSignal West Pico Chemiluminescent substrate kit for PPI cat–ELCCA were 
purchased from Pierce. eIF4E (9742), 4E–BP1 (9644) and eIF4G (2858) antibodies were 
purchased from Cell Signaling Technology.  
 
General peptide synthesis methods. 4E–BP1 and eIF4G stapled peptides were synthesized on a 
0.2–mmol scale in a 20–mL fritted syringe using MBHA Rink amide resin (0.2 – 0.4 mmol/g 
loading). In brief, the resin was swelled for 20 min at 25 °C in 1:1 DMF:DCM. FMOC groups 
were removed following the addition of a 20% piperidine/DMF solution (10 mL) and gentle 
agitation for a total of 20 min at 25°C. After each FMOC deprotection and amino acid couplings, 
the resin was thoroughly washed with NMP, CH2Cl2, and DMF. Amino acid couplings were 
performed by addition of amino acid (1 mmol) pre–activated with HBTU (0.9 mmol), N,N–
diisopropylethylamine (2 mmol) in NMP (5 mL), and agitated for 2 – 3 h at 25 °C. The peptide 
was stapled on resin by bubbling nitrogen gas in DCE solution of Grubbs I or Grubbs II catalyst 
at 6 mM for at least two hours68. The reaction was monitored through 10 – 20 mg resin test 
cleaves on the LC–MS. The procedure was repeated until the substrate had completely depleted 
in the LC–MS, usually for a total of three replicates.  After stapling, the N–terminus was 
acetylated or modified with fluorescein isothiocyanate (FITC) (separated by 2 –alanine 
residues), and the peptide was cleaved from the resin 
using TFA/thioanisole/water/triisopropylsilane (90:4:4:2) for 4 h at 25 °C. The resulting solution 
was added to glacial ether (~200 mL) for peptide precipitation. The precipitates were 
then collected, dissolved, and purified via RP–HPLC. Fractions containing the desired peptide 
were confirmed by LC–MS, lyophilized, re–dissolved in 1:1 acetic acid:water, and lyophilized 
again. The non–fluoresceine labeled peptides were dissolved in de–gassed H2O. Fluoresceine 
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labeled peptides were dissolved in de–gassed 1:2 DMF:H2O v/v solution. All peptide stock 
solutions were centrifugal filtered (PVDF) prior to use. mHCS–i, mHCS–ii, HCS 4E–BP1, 
mHCS–5i, and mHCS–5ii NMR spectra were recorded on Varian 500MHz and Bruker DRX 
600 MHz instrument.  
4.6.2 CELLULAR TREATMENTS 
Preparation of m7GDP resin. m7GDP resin synthesis was adapted from that reported86. m7GDP 
sodium salt (2.3 mg; Sigma) was dissolved in water (500 L), and a solution of sodium periodate 
(1.1 mg) in sodium acetate buffer (100 L; 0.1M, pH 6) was added. The resulting mixture was 
agitated at room temperature for 30 min protected from light. Adipic acid dihydrazide agarose (1 
mL packed; Sigma) was washed with water (1 20 mL) followed by sodium acetate buffer (1 
20mL), and then re–suspended in sodium acetate buffer (2 mL). To this slurry was added with 
aniline (10 L) and the oxidized m7GDP solution. The resin mixture was then shaken at room 
temperature for 45 min before adding sodium cyanoborohydride (5 mg) and agitated overnight at 
4 C. The resin was washed with NaCl (1M; 5 5 mL), equilibrated in buffer A (5 mL; 50 mM 
HEPES, pH 7, 200 mM KCl), and stored at 4 C.  
 
m7G cap affinity assay. The cap pull–down assay was carried out as previously described87. 
Briefly, MDA–MB–231, HCT116, and H1299 cells were grown in 6–cm dishes and treated with 
peptides for 6 h. Cells were then lysed in cap pull–down buffer (50 mM HEPES–KOH (pH 7.5), 
150 mM KCl, 1 mM EDTA, 2 mM DTT and 0.1% Tween 20) containing protease inhibitors. 
Cell lysate was centrifuged at 15,000 rpm for 25 min. The supernatant was subsequently 
incubated for 2 h at 4 °C with m7GDP–agarose resin. Beads were washed 3 with the cap pull–
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down buffer, 1 with TBS and 1 with water. Proteins were eluted by boiling in 2× LDS sample 
buffer for 10 min at 70 °C, resolved on a 4−12% Bis–Tris gel, and transferred to PVDF 
membrane in Towbin’s Buffer. The membrane was blocked in 5% milk for 1 h at 25 °C, and 
then incubated with a primary antibody (overnight at 4 °C) and secondary antibody (1 h at 25 
°C). Proteins were visualized by autoradiography. In all cases, the eIF4E level was used for 
normalization. 
 
Flow cytometry. MDA–MB–231 cells were grown in 6–well plates and treated with peptides at 
1.0 M for 6 h. Cells were harvested with trypsin and washed once with ice–cold 1 PBS. The 
cells were then re–suspended in 300 l of ice–cold 1 PBS, and 1 l of 50 g/mL propidium 
iodide (Sigma) was added and incubated for 10 min. Cells were then filtered before acquiring 
data using a Cytoflex flow cytometer (Beckman). Median cell fluorescence of propidium iodide 
negative cells was determined using FlowJo (v10). 
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CHAPTER 5 FUTURE DIRECTIONS 
 
eIF4F is a critical regulatory nexus that is often hyperactivated in cancerous cells to 
stimulate the translation of a specific subset of mRNA that drive transformation. While the 
normal nonmalignant cells can tolerate a broad range of eIF4F activity, malignant cells require a 
constitutively active eIF4F complex to maintain their pathological state. In fact, a normalization 
rather than a complete inhibition of the eIF4F complex activity was sufficient to induce apoptosis 
in cancer cells1 while leaving untransformed cells alive. A successful agent targeting the eIF4F 
complex could require significantly lower dosage, reduce the overall toxicity, and be selective 
for the protein translation addicted cancerous cells; it could be the true blade to the Achilles heel 
of cancer2. 
PPI cat-ELCCA was successfully used to conduct a screening campaign against the 
eIF4E–4E-BP1 interaction. The future direction for this versatile assay is to expand and apply it 
towards other target PPIs such as the eIF4G1–eIF4A interaction, the other critical interaction 
involved in the CdT initiation. The expression and purification of HT eIF4G1 can be transferred 
from HEK293T cells to Sf9 insect cells for higher yield, and eIF4G1 expressed from Sf9 cells 
have shown appropriate binding activities to target proteins3-5. In vitro expression and 
purification of eIF4A is well-documented6, and should require minor optimizations in identifying 
the active termini position of the HT to obtain the active HT eIF4A. 
Admittedly, PPI cat-ELCCA is more labor intensive than other common HTS assays (FP, 
TR-FRET) even with the aid of liquid washers and dispensers. The next step for HTS campaigns 
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using PPI cat-ELCCA (and other cat-ELCCAs) is more extensive assay automations. A 
significant bulk of the labor can be automated with the technological advancements of the liquid 
handling instrumentation like Biomek Dual FXP and its modular installations of washers, 
incubators, and dispensers. In addition, miniaturization using automated liquid and plate handlers 
can reduce or even remove potential operator error and allow for more consistent results over 
time. Currently, PPI cat-ELCCA is scripted for near-complete liquid and plate handling on the 
Biomek Dual FXP instrumentation at UM CCG; the evaluations of automated PPI cat-ELCCA 
will be insightful for further assay automation developed from the cat-ELCCA platform. 
The eIF4E interaction HTS campaigns yielded few validated NPE fractions and 
compounds exhibiting dose-dependent activities, which are currently being reproduced and 
procured for further validations. The complete characterization of active molecule(s) from the 
NPE and BIC libraries are on-going. First, the microbes are being re-cultured for re-isolation of 
the active NPE fractions. Following the re-isolation, the active fraction must then be subjected to 
iterative fractionation and screening processes to narrow down to the active compound(s), which 
will then require full chemical characterization and re-testing. The bioactive compound(s) will 
then be investigated for binding affinity to target eIF4E protein by SPR and assayed for eIF4E 
interaction disruption in cellulo by m7GDP-agarose pulldown experiments. Pending 
confirmations from both SPR and in cellulo analysis, medicinal chemistry campaign and SAR 
studies will be conducted in parallel to solving the compound-protein complex structure. Clearly, 
this is more time and resource consuming than a typical follow-up studies of hits identified from 
the commercially available compound libraries; however, the NPE libraries contain vastly more 
complex chemical identities that may indeed be necessary to target complex PPIs and be worth 
the initial investment. Furthermore, commercially available libraries have already been screened 
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against which led to discoveries of 4E1RCat7 and 4EGI-18; thus, screening against new chemical 
libraries was essential for this HTS campaign. 
Similarly, custom BIC libraries from Eli Lilly offered a rare access to the unexplored 
chemical space by both of the prior HTS campaigns against eIF4E interactions. Over 50% of the 
validated dose-responsive compounds showed direct binding to eIF4E, and the remaining 
compounds may disrupt the PPI in a novel mechanism (e.g. binding to 4E-BP1) that requires 
further investigation. A few of the hit compounds have met the criterion as set by OIDD, and 
efforts to obtain their chemical structures are on-going. Since the hits are representative 
compounds of the chemical scaffolds extensively researched by Eli Lilly, further collaborative 
investigations may lead to fast-tracked medicinal chemistry campaigns in which additional 
analogues are supplied through OIDD and screened using PPI cat-ELCCA and SPR. Ultimately, 
a successful collaboration with Eli Lilly will accelerate the discovery and confirmations of novel 
inhibitors of the CdT initiation. 
The Garner group discovered that the HCS peptides mimicking 4E-BM of 4E-BP1 
showed increased binding affinity over the linear 4E-BP1 peptide and inhibited the eIF4E 
interactions in presence of FBS in cellulo. The synthesis and characterizations of mHCS 4E-BP1 
were riddled with challenges, and in the advent of HCS 4E-BP1 having superior activity with 
significantly easier sample preparations, mHCS 4E-BP1 research is no longer being pursued by 
the Garner group. Contrary to the hypothesis that significant librational motions of the peptide on 
the binding interface may be beneficial9, mHCS 4E-BP1 studies concluded that implementing 
greater flexibility to the staple and decreasing the overall helicity of the mHCS 4E-BP1 does not 
increase the binding affinity. Although the emergence of mHCS 4E-BP1 isomers may of interest 
from a chemistry perspective – to explore and develop other Grubbs catalysts for RCM that 
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promote one isomer formation over the other –its practical application in stapled peptides are 
limited; most i, i+4 HCS peptides do not suffer from isomerization, and the higher flexibility of 
longer olefinic substrates of i, i+8 HCS peptides can achieve similar helicity by using two 
separate i, i+4 staples.  
The Garner group is currently characterizing the bioactivities of stapling strategies with 
minor differences like those between cis- and trans- isomers, specifically concerning the lactam 
stapled 4E-BP1 mimetics. By reversing the staple positions of the free carboxylate- and the free 
amino- functionalized unnatural amino acids of the lactam bond, two regioisomeric lactam 
stapled peptides are created. Preliminary in cellulo studies indicate that these regioisomers have 
different bioactivities and secondary structures. Alternatively, the cis- and trans- stapling 
strategies can be mimicked using thioether linkers and bis-cysteine peptides to investigate 
whether the hydrocarbon stapled regioisomers yields different bioactivities.  
In general, the optimizations of 4E-BP1 sequence for stapled peptide designs are still on-
going. Bioisostere substitutions of C62 and M60 in 4E-BP1 sequence could increase peptide 
stability in solution and eliminate or reduce sulfur oxidation. And although M60 substitutions 
have shown drastic loss in binding activity, C62 may be substituted with difluoro-functionalized 
unnatural amino acids10-11; despite the reported role of difluoro- analogues in decreasing the 
peptide helix propensities12-13, HCS strategy should limit this loss and improve the peptide 
stability and activity. HCS 4E-BP1 and 4E-BP1 peptide both have relatively poor solubility in 
water (< 1 mM), and further sequence optimizations using natural and unnatural amino acids as 
well as peptide truncations are currently on-going to increase the peptide solubilities. 
The two-pronged approach in targeting the CdT initiation encloses the described efforts 
to discover novel small molecule and HCS peptides to disrupt the eIF4E interactions and to 
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normalize the CdT initiation. Although the two approaches are distinct and separated, their 
potential outcomes will hopefully find a union in future studies. The eIF4E binding hit molecules 
can be cross-screened against eIF4E–eIF4G1 interaction to gain insight into whether the hit 
compounds bind competitively to the canonical binding motif or allosterically towards the cap-
binding site. Hot spot modulators of eIF4E can open the path to the identification of scaffolds 
that can disrupt eIF4F complexes; furthermore, the chemical scaffold could be leveraged as 
potential unnatural side-chain designs for the future stapled peptides. On the other hand, the 
allosteric modulators can be linked onto the 4E-BP1 stapled peptides to further enhance the 
probe binding affinity and potency, or to introduce cell permeability to the otherwise 
impermeable allosteric modulators. In summary, this work highlights the innovative approach in 
targeting the CdT initiation through the disruption and normalization of eIF4F complex through 
novel PPI screening assay to evaluate small molecule inhibitors and stapled peptides. 
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CIRCULAR DICHROISM SPECTRAS 
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